[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_8162add8-64dc-443b-84ef-acb717121ca9":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:8162add8-64dc-443b-84ef-acb717121ca9,\"}":36},{"code":4,"data":5,"meta":18},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":20,"manageAffiliations":21,"indexDatabases":22,"url":23,"thumbnailPath":18,"statistic":24,"gsStatistic":18,"type":35,"analyzePriority":18},"8162add8-64dc-443b-84ef-acb717121ca9","2024-04-20T10:22:10.695+00:00","2026-06-17T15:29:55.831+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Tim-m%E1%BA%A1ch-h%E1%BB%8Dc-Vi%E1%BB%87t-Nam",{"issn":12,"title":14},{"VOID":13},"18592848",{"VOID":15},"Tạp chí Tim mạch học Việt Nam","PUBLISHER","PENDING",null,0,[],[],[],"https:\u002F\u002Fjvc.vnha.org.vn\u002Ftmh",{"impactFactor":19,"impactFactorByYear":25,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":26,"totalPublicationByYear":27,"totalCitation":30,"totalCitationByYear":31,"totalCitationPerPublication":32,"totalCitationPerPublicationByYear":33,"hindexLast5Year":28,"hindex":28},{},12,{"2015":28,"2016":28,"2018":29,"2019":28,"2021":29,"2022":28,"2023":30},1,3,2,{"2015":28,"2018":28},0.17,{"2015":28,"2018":34},0.33,"JOURNAL",{"meta":37,"data":39},{"total":38},"26",[40,153,346,511,680,839,999,1105,1275,1400],{"id":41,"createTime":42,"updateTime":43,"relativeEntities":44,"slug":45,"properties":46,"entityType":54,"verifyStatus":55,"verifyTime":42,"verifyNote":56,"syncStatus":17,"languages":57,"translateLanguages":18,"viewCount":19,"primaryUrl":59,"fullTextUrl":60,"authors":61,"publicationType":110,"publisherRelationship":111,"citationCount":28,"citationInfo":130,"publishDate":133,"publishYear":131,"citationAnalyzeStatus":17,"lastCitationAnalyze":134,"indexDatabases":18,"openAccess":18,"references":135,"isForceReanalyzing":152},"4b89439f-4d50-405b-a989-907eec06067d","2025-02-24T04:10:28.492+00:00","2026-01-26T23:50:05.333+00:00",[],"Gi%C3%A1-tr%E1%BB%8B-c%E1%BB%A7a-nghi%E1%BB%87m-ph%C3%A1p-k%C3%ADch-th%C3%ADch-th%E1%BA%A5t-s%E1%BB%9Bm-%E1%BB%9F-th%E1%BB%9Di-k%E1%BB%B3-tr%C6%A1-c%E1%BB%A7a-b%C3%B3-His-trong-ch%E1%BA%A9n-%C4%91o%C3%A1n-ph%C3%A2n-bi%E1%BB%87t-c%C6%A1n-nh%E1%BB%8Bp-nhanh-k%E1%BB%8Bch-ph%C3%A1t-tr%C3%AAn-th%E1%BA%A5t",{"keywords":47,"gsPaper":48,"abstract":50,"title":52},{},{"VOID":49},"[\"11701260753413151610\"]",{"VI":51},"Mục tiêu: Nghiên cứu này xác định giá trị của nghiệm pháp kích thích (KT) thất sớm ở thời kỳ trơ của bó His trong cơn tim nhanh để chẩn đoán phân biệt cơn nhịp nhanh kịch phát trên thất.\r\nPhương pháp nghiên cứu: 75 bệnh nhân (BN) cơn nhịp nhanh kịch phát trên thất (NNKPTT) được tiến hành thăm dò điện sinh lý tim và triệt đốt thành công bằng năng lượng sóng có tần số Radio (RF) tại Viện Tim mạch Việt Nam. Trong đó có 43 bệnh nhân (chiếm 57.3%) cơn nhịp nhanh vòng vào lại nút nhĩ thất (AVNRT) và 32 bệnh nhân (chiếm 42.7%) cơn nhịp nhanh vòng vào lại nhĩ thất (AVRT). Trong cơn nhịp nhanh, chúng tôi tiến hành KT thất sớm ở mỏm thất phải với khoảng ghép ngắn dần (V2). Tại điện đồ vùng cao nhĩ phải (HRA) khoảng điện đồ nhĩ trong cơn nhịp nhanh đến điện đồ nhĩ dẫn truyền (DT) ngược khi KT thất sớm (A1A2) được đo và so sánh với chiều dài chu kỳ cơn nhịp nhanh (A1A1). Chỉ số ∆ AA (∆ AA = A1A1 A1A2) phản ánh hoạt động nhĩ sớm khi KT thất sớm ở thời kỳ trơ của bó His trong cơn nhịp nhanh. Kết quả: Chỉ số ∆AA ở nhóm BN cơn AVRT lớn hơn có ý nghĩa thống kê so với nhóm cơn AVNRT (15.8 ± 12.6 so với 1.2 ± 1.6 với p < 0.05). Đặc biệt, chỉ số ∆ AA ở nhóm AVRT có đường DT phụ vùng vách lớn hơn nhiều và có ý nghĩa thống kê so với nhóm AVNRT thể không điển hình (31.2 ± 13.3 so với 2.2 ± 1.6 với p < 0.05). Như vậy: Nghiệm pháp KT thất sớm ở thời kỳ trơ của bó His trong cơn tim nhanh có giá trị cao trong chẩn đoán phân biệt cơn AVNRT và cơn AVRT với điểm cắt được chọn làm 4.5 ms (AUC: 98.8%, độ nhạy: 93.8%, độ đặc hiệu: 95.3%) và rất có giá trị trong trong chẩn đoán phân biệt cơn AVRT có đường dẫn truyền phụ nằm ở vùng vách và cơn AVNRT thể không điển hình với điểm cắt được lựa chọn là 10 ms (AUC: 100%, độ nhạy và độ đặc hiệu là 100%).\r\nKết luận: Sử dụng KT thất sớm vào thời kỳ trơ của bó His trong cơn tim nhanh rất có giá trị trong chẩn đoán phân biệt cơn AVRT và cơn AVNRT. Đặc biệt trong chẩn đoán phân biệt cơn AVRT có đường dẫn truyền phụ nằm ở vùng vách và cơn AVNRT thể không điển hình.",{"VI":53},"Giá trị của nghiệm pháp kích thích thất sớm ở thời kỳ trơ của bó His trong chẩn đoán phân biệt cơn nhịp nhanh kịch phát trên thất","PUBLICATION","VERIFIED","Auto Verify",[58],"VI","http:\u002F\u002Fjvc.vnha.org.vn\u002Ftmh\u002Farticle\u002Fview\u002F241","http:\u002F\u002Fjvc.vnha.org.vn\u002Ftmh\u002Farticle\u002Fdownload\u002F241\u002F272",[62,80,97],{"id":63,"sortIndex":19,"researcher":18,"roles":64,"affiliations":65,"properties":77},"054d8072-0f47-4620-ac9a-260a5952bff7",[],[66],{"id":67,"sortIndex":19,"affiliation":68,"properties":18},"9428acaa-bbb9-4cbd-81d5-78157413d360",{"id":69,"createTime":70,"updateTime":70,"relativeEntities":71,"slug":72,"properties":73,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"de867861-1cbb-490f-ac13-986f2be353da","2025-10-14T02:50:42.479+00:00",[],"B%E1%BB%87nh-vi%E1%BB%87n-%C4%90a-khoa-t%E1%BB%89nh-Qu%E1%BA%A3ng-Ninh",{"title":74},{"EN":75},"Bệnh viện Đa khoa tỉnh Quảng Ninh","AFFILIATION",{"title":78},{"EN":79},"Phan Thanh Nghĩa",{"id":81,"sortIndex":30,"researcher":18,"roles":82,"affiliations":83,"properties":94},"14bbe4bd-0f32-46ac-b2f8-7ff543a42661",[],[84],{"id":85,"sortIndex":19,"affiliation":86,"properties":18},"b491f914-4c1b-4a22-a54d-79d7a46f916e",{"id":87,"createTime":88,"updateTime":88,"relativeEntities":89,"slug":90,"properties":91,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"6b6cf0d9-2822-4dbf-a25c-63bf7a8193a2","2026-01-20T10:24:01.948+00:00",[],"Vi%E1%BB%87n-Tim-m%E1%BA%A1ch-Vi%E1%BB%87t-Nam-B%E1%BB%87nh-vi%E1%BB%87n-B%E1%BA%A1ch-Mai",{"title":92},{"VI":93},"Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai",{"title":95},{"EN":96},"Nguyễn Thị Mai Ngọc",{"id":98,"sortIndex":28,"researcher":18,"roles":99,"affiliations":100,"properties":107},"4724b7b7-1bc6-44af-b8be-6821a0063c85",[],[101],{"id":102,"sortIndex":19,"affiliation":103,"properties":18},"1258e082-87a3-46c7-9082-14583cfc9dea",{"id":87,"createTime":88,"updateTime":88,"relativeEntities":104,"slug":90,"properties":105,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":106},{"VI":93},{"title":108},{"EN":109},"Trần Song Giang","ARTICLE",{"url":18,"publisher":112,"properties":125},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":113,"slug":10,"properties":114,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":117,"manageAffiliations":118,"indexDatabases":119,"url":23,"thumbnailPath":18,"statistic":120,"gsStatistic":18,"type":35,"analyzePriority":18},[],{"issn":115,"title":116},{"VOID":13},{"VOID":15},[],[],[],{"impactFactor":19,"impactFactorByYear":121,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":26,"totalPublicationByYear":122,"totalCitation":30,"totalCitationByYear":123,"totalCitationPerPublication":32,"totalCitationPerPublicationByYear":124,"hindexLast5Year":28,"hindex":28},{},{"2015":28,"2016":28,"2018":29,"2019":28,"2021":29,"2022":28,"2023":30},{"2015":28,"2018":28},{"2015":28,"2018":34},{"pages":126,"issue":128},{"VOID":127},"68-74",{"VOID":129},"90",{"total":28,"publishYear":131,"statisticByYear":132},2019,{},"2019-01-01","2026-01-26T23:50:05.332+00:00",[136,138,140,142,144,146,148,150],{"id":18,"text":137,"url":18,"identifiers":18},"1. OrejarenaL.A.,VidailletH.,DeStefanoF.vàcộngsự.(1998). Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol, 31(1), 150–157.",{"id":18,"text":139,"url":18,"identifiers":18},"2. Trohman RG (2000), “Supraventricular tachycardia: implications for the intensivist.”, Crit Care Med. 28, tr. 129-135.",{"id":18,"text":141,"url":18,"identifiers":18},"3. Epstein L.M., Chiesa N., Wong M.N. và cộng sự. (1994). Radiofrequency catheter ablation in the treatment of supraventricular tachycardia in the elderly. J Am Coll Cardiol, 23(6), 1356–1362.",{"id":18,"text":143,"url":18,"identifiers":18},"4. Veenhuyzen G.D., Quinn F.R., Wilton S.B. và cộng sự. (2011). Diagnostic pacing maneuvers for supraventricular tachycardia: part 1. PacingClinElectrophysiol, 34(6), 767–782.",{"id":18,"text":145,"url":18,"identifiers":18},"5. ItoH.,BadhwarN.,PatelA.R.vàcộngsự.(2018). Use of Programmed Ventricular Extrastimulus During Supraventricular Tachycardia to Differentiate Atrioventricular Nodal Re-Entrant Tachycardia From Atrioventricular Re-Entrant Tachycardia. JACC Clin Electrophysiol, 4(7), 872–880.",{"id":18,"text":147,"url":18,"identifiers":18},"6. Đinh Hữu Bách, Trần Song Giang (2015), Nghiên cứu chẩn đoán đoán phân biệt cơn nhịp nhanh vòng vào lại nhĩ thất và cơn nhịp nhanh vòng vào lại tại nút nhĩ thất bằng phương pháp kích thích thất. Luận văn thạc sỹ y học, Trường Đại học Y Hà Nội.",{"id":18,"text":149,"url":18,"identifiers":18},"7. TrầnHồngQuân,TrầnSongGiangvàNguyễnLânHiếu(2018). Nghiên cứu giá trị của chỉ số PPI – TCL và SA – VA trong chẩn phân biệt cơn nhịp nhanh do vòng vào lại tại nút nhĩ thất và cơn nhịp nhanh do vòng vào lại nhĩ thất. Luận văn thạc sỹ y học, Trường Đại học Y Hà nội.",{"id":18,"text":151,"url":18,"identifiers":18},"8. Porter MJ1, Morton JB và Denman R (2004). “Influence of age and gender on the mechanism of supraventricular tachycardia”, Heart Rhythm.",false,{"id":154,"createTime":155,"updateTime":156,"relativeEntities":157,"slug":158,"properties":159,"entityType":54,"verifyStatus":55,"verifyTime":167,"verifyNote":56,"syncStatus":17,"languages":168,"translateLanguages":18,"viewCount":19,"primaryUrl":169,"fullTextUrl":170,"authors":171,"publicationType":110,"publisherRelationship":280,"citationCount":19,"citationInfo":299,"publishDate":301,"publishYear":131,"citationAnalyzeStatus":302,"lastCitationAnalyze":156,"indexDatabases":18,"openAccess":18,"references":303,"isForceReanalyzing":152},"0ffe2952-d669-4c15-98e4-7d4d93962658","2024-11-25T18:34:42.604+00:00","2026-05-16T21:37:21.082+00:00",[],"R%E1%BB%91i-lo%E1%BA%A1n-ch%E1%BB%A9c-n%C4%83ng-th%E1%BA%ADn-%E1%BB%9F-b%E1%BB%87nh-nh%C3%A2n-tim-b%E1%BA%A9m-sinh-ng%C6%B0%E1%BB%9Di-l%E1%BB%9Bn-v%C3%A0-c%C3%A1c-y%E1%BA%BFu-t%E1%BB%91-li%C3%AAn-quan",{"keywords":160,"gsPaper":161,"abstract":163,"title":165},{},{"VOID":162},"930691213892245242",{"VI":164},"Mục tiêu nghiên cứu: Tại Việt Nam, các hiểu biết về chức năng thận ở người lớn mắc tim bẩm sinh (TBS) còn hạn chế. Nghiên cứu này nhằm xác định tỉ lệ rối loạn chức năng thận, và các yếu tố liên quan đến rối loạn chức năng thận ở người lớn mắc TBS.\r\nPhương pháp nghiên cứu: Đây là nghiên cứu mô tả cắt ngang, gồm 230 bệnh nhân TBS >16 tuổi. Các thông tin được thu thập bao gồm ure, creatinine huyết thanh, mức lọc cầu thận (MLCT), tuổi, giới, phân suất tống máu thất trái, NT-proBNP huyết thanh, tăng áp động mạch phổi, rung nhĩ, thiếu máu, đa hồng cầu. Tỉ suất chênh (OR) cho MLCT <90ml\u002Fphút\u002F1.73 m2 da được xác định.Kết quả: 73.1% bệnh nhân có rối loạn chức năng thận, bao gồm 9.6% có MLCT >120 ml\u002Fphút\u002F1.73 m2 da và 63.5% có MLCT <90 ml\u002Fphút\u002F1.73 m2 da. Ở bệnh nhân TBS shunt trái-phải, tỉ suất chênh OR bằng 6.58 (CI95%: 1.50 – 28.96) lần so sánh giữa nhóm tuổi >60 và ≤60, và tỉ suất chênh OR bằng 2.65 (CI95%: 1.24 – 5.67) lần khi so sánh giữa nhóm SpO2 < 95% và SpO2 ≥95%.\r\nKết luận: Rối loạn chức năng thận là thường gặp ở TBS người lớn. Các yếu tố liên quan đến rối loạn chức năng thận ở là tuổi >60 và SpO2 <95%.\r\nTừ khóa: Rối loạn chức năng thận, tim bẩm sinh, người lớn",{"VI":166},"Rối loạn chức năng thận ở bệnh nhân tim bẩm sinh người lớn và các yếu tố liên quan","2024-11-25T18:34:42.603+00:00",[58],"https:\u002F\u002Fjvc.vnha.org.vn\u002Ftmh\u002Farticle\u002Fview\u002F372","https:\u002F\u002Fjvc.vnha.org.vn\u002Ftmh\u002Farticle\u002Fdownload\u002F372\u002F356",[172,187,201,214,247,260],{"id":173,"sortIndex":19,"researcher":18,"roles":174,"affiliations":175,"properties":182},"cc7fae4c-5ef5-4b4f-9e56-8f97d5c77363",[],[176],{"id":177,"sortIndex":19,"affiliation":178,"properties":18},"b61bcc50-223e-4c18-a828-e29951531da0",{"id":87,"createTime":88,"updateTime":88,"relativeEntities":179,"slug":90,"properties":180,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":181},{"VI":93},{"gsAuthor":183,"title":185},{"VOID":184},"chicgEwAAAAJ",{"EN":186},"Kim Ngọc Thanh",{"id":188,"sortIndex":189,"researcher":18,"roles":190,"affiliations":191,"properties":198},"5f5f2037-78e8-40fc-bebe-71fff516cd02",5,[],[192],{"id":193,"sortIndex":19,"affiliation":194,"properties":18},"9dbab2fc-27e2-4674-987e-c913055f9108",{"id":87,"createTime":88,"updateTime":88,"relativeEntities":195,"slug":90,"properties":196,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":197},{"VI":93},{"title":199},{"EN":200},"Trương Thanh Hương",{"id":202,"sortIndex":203,"researcher":18,"roles":204,"affiliations":205,"properties":212},"74fa8956-cbff-474f-bb0c-6fdf25ddb7b9",4,[],[206],{"id":207,"sortIndex":19,"affiliation":208,"properties":18},"4a861d47-702f-4f84-a50a-7371720eeb64",{"id":87,"createTime":88,"updateTime":88,"relativeEntities":209,"slug":90,"properties":210,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":211},{"VI":93},{"title":213},{"EN":96},{"id":215,"sortIndex":28,"researcher":18,"roles":216,"affiliations":217,"properties":244},"126a8e33-f80f-48e3-b124-85371e452d28",[],[218],{"id":219,"sortIndex":19,"affiliation":220,"properties":241},"a55eaa32-6b9e-4bf1-bfd1-0becb52813da",{"id":221,"createTime":222,"updateTime":223,"relativeEntities":224,"slug":225,"properties":226,"entityType":76,"verifyStatus":55,"verifyTime":237,"verifyNote":18,"syncStatus":17,"languages":238,"translateLanguages":18,"viewCount":240},"fbda2311-d0c4-4fac-aba0-6b61a38a8301","2023-07-03T07:02:15.519+00:00","2026-06-19T02:14:17.591+00:00",[],"Tr%C6%B0%E1%BB%9Dng-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Y-H%C3%A0-N%E1%BB%99i",{"country":227,"title":229,"address":232,"abbreviation":235},{"VOID":228},"VN",{"EN":230,"VI":231},"Hanoi Medical University","Trường Đại học Y Hà Nội",{"VI":233,"EN":234},"Số 1 đường Tôn Thất Tùng, phường Trung Tự, quận Đống Đa, thành phố Hà Nội, Việt Nam","No. 01 Ton That Tung street, Trung Tu ward, Dong Da district, Hanoi city, Vietnam",{"VOID":236},"HMU","2023-08-01T14:25:42.012+00:00",[58,239],"EN",16,{"title":242},{"EN":243}," Đại học Y Hà Nội",{"title":245},{"EN":246},"Phan Nhật Quang",{"id":248,"sortIndex":29,"researcher":18,"roles":249,"affiliations":250,"properties":257},"7ac6b27f-1b15-4ecc-9783-77e47020d5fb",[],[251],{"id":252,"sortIndex":19,"affiliation":253,"properties":18},"64653f32-12ac-46e1-bb9e-9792deede48b",{"id":87,"createTime":88,"updateTime":88,"relativeEntities":254,"slug":90,"properties":255,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":256},{"VI":93},{"title":258},{"EN":259},"Lê Thanh Tùng",{"id":261,"sortIndex":30,"researcher":18,"roles":262,"affiliations":263,"properties":277},"58398114-f9f0-4b47-86c1-350c9e05534f",[],[264],{"id":265,"sortIndex":19,"affiliation":266,"properties":274},"14038f29-ccda-46b0-9bff-1bb0285e9ae3",{"id":221,"createTime":222,"updateTime":223,"relativeEntities":267,"slug":225,"properties":268,"entityType":76,"verifyStatus":55,"verifyTime":237,"verifyNote":18,"syncStatus":17,"languages":273,"translateLanguages":18,"viewCount":240},[],{"country":269,"title":270,"address":271,"abbreviation":272},{"VOID":228},{"EN":230,"VI":231},{"VI":233,"EN":234},{"VOID":236},[58,239],{"title":275},{"EN":276},"Đại học Y Hà Nội",{"title":278},{"EN":279},"Đinh Thị Kim Dung",{"url":18,"publisher":281,"properties":294},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":282,"slug":10,"properties":283,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":286,"manageAffiliations":287,"indexDatabases":288,"url":23,"thumbnailPath":18,"statistic":289,"gsStatistic":18,"type":35,"analyzePriority":18},[],{"issn":284,"title":285},{"VOID":13},{"VOID":15},[],[],[],{"impactFactor":19,"impactFactorByYear":290,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":26,"totalPublicationByYear":291,"totalCitation":30,"totalCitationByYear":292,"totalCitationPerPublication":32,"totalCitationPerPublicationByYear":293,"hindexLast5Year":28,"hindex":28},{},{"2015":28,"2016":28,"2018":29,"2019":28,"2021":29,"2022":28,"2023":30},{"2015":28,"2018":28},{"2015":28,"2018":34},{"pages":295,"issue":297},{"VOID":296},"12-20",{"VOID":298},"87",{"total":19,"publishYear":131,"statisticByYear":300},{},"2019-04-01","DONE_ANALYZE_CITATION",[304,306,308,310,312,314,316,318,320,322,324,326,328,330,332,334,336,338,340,342,344],{"id":18,"text":305,"url":18,"identifiers":18},"1. Baumgartner H, Bonhoeffer P, De Groot NM, et al. ESC Guidelines for the management of grown-up congenital heart disease version 2010. Eur Heart J. 2010 Dec;31(23):2915-57.",{"id":18,"text":307,"url":18,"identifiers":18},"2. Torres-Cosme, Rolón, Aguinaga M, et al. Mortality from Congenital Heart Disease in Mexico: A Problem on the Rise. PLoS One. 2016 Mar 3;11(3):e0150422.",{"id":18,"text":309,"url":18,"identifiers":18},"3. Naidu P, Grigg L, Zentner D. Mortality in adults with congenital heart disease. Int J Cardiol. 2017 Oct 15;245:125-130.",{"id":18,"text":311,"url":18,"identifiers":18},"4. Amanda L.H, Lorna Swan. Quality of life in adults living with congenital heart disease: beyond morbidity and mortality. J Thorac Dis. 2016 Dec;8(12):E1632-E1636.",{"id":18,"text":313,"url":18,"identifiers":18},"5. Catherine M, Mohammed A.A, Gonzalo G.G. Chronic kidney disease in congenital heart disease patients: a narrative review of evidence. Can J Kidney Health Dis. 2015 Aug 11;2:27.",{"id":18,"text":315,"url":18,"identifiers":18},"6. Agras P.I, Derbent M, Ozcay F, et al. Effect of congenital heart disease on renal function in childhood. Nephron Physiol. 2005;99(1):p10-5.",{"id":18,"text":317,"url":18,"identifiers":18},"7. Krull F, Ehrich J.H, Wurster U, et al. Renal involvement in patients with congenital cyanotic heart disease. Acta Paediatr Scand. 1991 Dec;80(12):1214-9.",{"id":18,"text":319,"url":18,"identifiers":18},"8. Ariane J.M, Andrew S. M, Raluca I, et al. Congenital Heart Disease in the General Population: Changing Prevalence and Age Distribution. Circulation. 2007 Jan 16;115(2):163-72. Epub 2007 Jan 8.",{"id":18,"text":321,"url":18,"identifiers":18},"9. P. Engelfriet, B.J.M. Mulder. Gender differences in adult congenital heart disease. Neth Heart J. 2009 Nov;17(11):414-7.",{"id":18,"text":323,"url":18,"identifiers":18},"10. Graham J.R, Gary D.W, Mor Barzel M.A. Estimates of Life Expectancy by Adolescents and Young Adults With Congenital Heart Disease. J Am Coll Cardiol. 2006 Jul 18;48(2):349-55. Epub 2006 Jun 22.",{"id":18,"text":325,"url":18,"identifiers":18},"11. Paniagua R, Ramos A, Fabian R, et al. Chronic kidney disease and dialysis in Mexico. Perit Dial Int. 2007 Jul-Aug;27(4):405-9.",{"id":18,"text":327,"url":18,"identifiers":18},"12. Cobo G, Hecking M, Port FK, et al. Sex and gender differences in chronic kidney disease: progression to end-stage renal disease and haemodialysis. Clin Sci (Lond). 2016 Jul 1;130(14):1147-63.",{"id":18,"text":329,"url":18,"identifiers":18},"13. Davies D.F, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow and tubular excretory capacity in adult males. J Clin Invest. 1950 May;29(5):496-507.",{"id":18,"text":331,"url":18,"identifiers":18},"14. Collins A.J, Foley R.N, Chavers B, et al. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & endstage renal disease in the United States. Am J Kidney Dis. 2012 Jan;59(1 Suppl 1):A7, e1-420.",{"id":18,"text":333,"url":18,"identifiers":18},"15. N.P. Nickel, O’Leary, E.L Brittain, et al. Kidney dysfunction in patients with pulmonary arterial hypertension. Pulm Circ. 2017 Mar 13;7(1):38-54.",{"id":18,"text":335,"url":18,"identifiers":18},"16. Chan Soon Park, Jin Joo Park, Young Oh, et al. Relation of Renal Function with Left Ventricular Systolic Function and NT-proBNP Level and Its Prognostic Implication in Heart Failure with Preserved versus Reduced Ejection Fraction: an analysis from the Korean Heart Failure (KorHF) Registry. Korean Circ J. 2017 Sep;47(5):727-741.",{"id":18,"text":337,"url":18,"identifiers":18},"17. Franczyk B, Gluba B.A, Ciałkowska-Rysz, et al. The Problem of Atrial Fibrillation in Patients with Chronic Kidney Disease. Curr Vasc Pharmacol. 2016;14(3):260-5.",{"id":18,"text":339,"url":18,"identifiers":18},"18. Donald S.S, Dov Wexler, Adrian Iaina, et al. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron? J Nephrol. 2004 Nov-Dec;17(6):749-61.",{"id":18,"text":341,"url":18,"identifiers":18},"19. Yosuke Hirakawa, Tetsuhiro Tanaka, Masaomi Nangaku. Renal Hypoxia in CKD; Pathophysiology and Detecting Methods. Front Physiol. 2017 Feb 21;8:99.",{"id":18,"text":343,"url":18,"identifiers":18},"20. Truong L.D, Farhood A, Tasby J, et al. Experimental chronic renal ischemia: morphologic and immunologic studies. Kidney Int. 1992 Jun;41(6):1676-89.",{"id":18,"text":345,"url":18,"identifiers":18},"21. Perloff J.K, Latta H, Barsotti P. Pathogenesis of the glomerular abnormality in cyanotic congenital heart disease. Am J Cardiol. 2000 Dec 1;86(11):1198-204.",{"id":347,"createTime":348,"updateTime":349,"relativeEntities":350,"slug":351,"properties":352,"entityType":54,"verifyStatus":55,"verifyTime":360,"verifyNote":56,"syncStatus":17,"languages":361,"translateLanguages":18,"viewCount":19,"primaryUrl":362,"fullTextUrl":363,"authors":364,"publicationType":110,"publisherRelationship":415,"citationCount":19,"citationInfo":429,"publishDate":432,"publishYear":430,"citationAnalyzeStatus":302,"lastCitationAnalyze":433,"indexDatabases":18,"openAccess":18,"references":434,"isForceReanalyzing":152},"da295352-a074-4cf2-988f-14d3cb1616d4","2024-04-11T18:09:23.516+00:00","2026-05-20T21:05:12.132+00:00",[],"Y%E1%BA%BFu-t%E1%BB%91-di-truy%E1%BB%81n-trong-b%E1%BB%87nh-l%C3%BD-%C4%91%E1%BB%99ng-m%E1%BA%A1ch-v%C3%A0nh-vai-tr%C3%B2-c%E1%BB%A7a-c%C3%A1c-nghi%C3%AAn-c%E1%BB%A9u-li%C3%AAn-quan-%C4%91%E1%BA%BFn-sinh-h%E1%BB%8Dc-ph%C3%A2n-t%E1%BB%AD",{"keywords":353,"gsPaper":354,"abstract":356,"title":358},{},{"VOID":355},"14093785667933274826",{"VI":357},"Bệnh tim mạch là một trong những nguyên nhân gây tử vong hàng đầu thế giới. Ở Việt Nam, 1\u002F4 số người tử vong mỗi năm do mắc các vấn đề về tim mạch, trong đó bệnh lý động mạch vành (ĐMV) là một trong những nguyên nhân thường gặp nhất.\r\nVề mặt lâm sàng, xơ vữa động mạch do hậu quả của sự lắng đọng cholesterol và quá trình viêm trong thành động mạch, cả hai đều được kích hoạt bởi các yếu tố nguy cơ truyền thống như tăng huyết áp, tăng lipid máu hoặc đái tháo đường. Một yếu tố nguy cơ khác là đột biến gen được xác định ở cá thể có tiền sử gia đình dương tính. Trong những năm gần đây, nhiều nghiên cứu sinh học phân tử đã xác định vai trò tác động mạch mẽ của các biến thể di truyền đến biểu hiện của xơ vữa ĐMV. Kết quả là đã có164 locus (vị trí) trên nhiễm sắc thể (NST) được xác định bởi các nghiên cứu liên kết trên toàn bộ hệ gen (GWAS) tác động tới nguy cơ mắc bệnh ĐMV. Trên thực tế nghiên cứu, tất cả các đột biến gen nguy cơ được phát hiện bởi GWAS thường được tìm thấy trong quần thể dân số chung, như mỗi cá thể khu vực Tây Âu mang từ 130 đến 190 alen nguy cơ tại các locus đã được biết đến trong toàn bộ hệ gen (có 0, 1 hoặc 2 alen nguy cơ trên mỗi locus). Có thể giả định rằng, cách phân bố đa dạng này khiến cho con người dễ bị ảnh hưởng bởi các yếu tố lối sống, làm tăng nguy cơ xơ vữa ĐMV. Cho đến nay, đã có nhiều đột biến gen liên quan đến nguy cơ bệnh ĐMV đã được phát hiện và các nhà khoa học đã cố gắng nhóm các đột biến gen này vào trong các nhóm chức năng để từ đó đưa ra các quan điểm phòng ngừa hoặc điều trị. Tại Việt Nam, từ năm 2013, sau khi phát hiện đột biến gen Fibrinogen beta (FGB) ở một bệnh nhân nhồi máu cơ tim (NMCT) có cơ địa dễ hình thành huyết khối, đã có nhiều nghiên cứu khác trong lĩnh vực này được tiến hành nhằm xác định các đột biến gen mới trong các bệnh lý tim mạch nói chung và bệnh lý ĐMV nói riêng. Điều này có ý nghĩa rất lớn trong việc ghi nhận đặc điểm đột biến gen tác động đến tỉ lệ mắc bệnh lý ĐMV nói riêng ở Việt Nam, góp phần thay đổi nhận thức của nhân viên y tế trong sàng lọc, chẩn đoán cũng như điều trị các yếu tố nguy cơ liên quan đến đột biến gen cũng như các tổn thương tim mạch liên quan.",{"VI":359},"Yếu tố di truyền trong bệnh lý động mạch vành - vai trò của các nghiên cứu liên quan đến sinh học phân tử","2025-01-10T03:32:12.164+00:00",[58],"https:\u002F\u002Fjvc.vnha.org.vn\u002Ftmh\u002Farticle\u002Fview\u002F417","https:\u002F\u002Fjvc.vnha.org.vn\u002Ftmh\u002Farticle\u002Fdownload\u002F417\u002F401",[365,388,402],{"id":366,"sortIndex":28,"researcher":18,"roles":367,"affiliations":368,"properties":386},"82eb6d17-4c41-4638-967f-9c1245d2c872",[],[369],{"id":370,"sortIndex":19,"affiliation":371,"properties":383},"93acb99c-ab1b-49b5-8b00-beb1b487aacc",{"id":372,"createTime":373,"updateTime":374,"relativeEntities":375,"slug":376,"properties":377,"entityType":76,"verifyStatus":55,"verifyTime":382,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":26},"053efbfe-ef28-4a48-8865-fe5d3062fa75","2023-05-09T03:41:34.226+00:00","2026-06-19T02:13:31.221+00:00",[],"Vietnam%20National%20Heart%20Institute%2C%20Bach%20Mai%20Hospital",{"country":378,"title":379},{"VOID":228},{"EN":380,"VI":381},"Vietnam National Heart Institute, Bach Mai Hospital","Viện Tim Mạch Việt Nam, Bệnh Viện Bạch Mai","2023-08-10T14:10:55.481+00:00",{"title":384},{"EN":385}," Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai",{"title":387},{"EN":96},{"id":389,"sortIndex":30,"researcher":18,"roles":390,"affiliations":391,"properties":397},"2557dbd8-3ade-4d8a-998a-02953b5fe50b",[],[392],{"id":18,"sortIndex":19,"affiliation":393,"properties":18},{"id":87,"createTime":88,"updateTime":88,"relativeEntities":394,"slug":90,"properties":395,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":396},{"VI":93},{"gsAuthor":398,"title":400},{"VOID":399},"u7Y3lwwAAAAJ",{"EN":401},"Nguyễn Thị Duyên",{"id":403,"sortIndex":19,"researcher":18,"roles":404,"affiliations":405,"properties":411},"62ff1793-956d-4c68-af45-b26fde14114c",[],[406],{"id":18,"sortIndex":19,"affiliation":407,"properties":18},{"id":87,"createTime":88,"updateTime":88,"relativeEntities":408,"slug":90,"properties":409,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":410},{"VI":93},{"gsAuthor":412,"title":414},{"VOID":413},"gvDwpdYAAAAJ",{"EN":200},{"url":18,"publisher":416,"properties":18},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":417,"slug":10,"properties":418,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":421,"manageAffiliations":422,"indexDatabases":423,"url":23,"thumbnailPath":18,"statistic":424,"gsStatistic":18,"type":35,"analyzePriority":18},[],{"issn":419,"title":420},{"VOID":13},{"VOID":15},[],[],[],{"impactFactor":19,"impactFactorByYear":425,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":26,"totalPublicationByYear":426,"totalCitation":30,"totalCitationByYear":427,"totalCitationPerPublication":32,"totalCitationPerPublicationByYear":428,"hindexLast5Year":28,"hindex":28},{},{"2015":28,"2016":28,"2018":29,"2019":28,"2021":29,"2022":28,"2023":30},{"2015":28,"2018":28},{"2015":28,"2018":34},{"total":19,"publishYear":430,"statisticByYear":431},2018,{},"2018-10-01","2026-05-20T21:05:12.131+00:00",[435,437,439,441,443,445,447,449,451,453,455,457,459,461,463,465,467,469,471,473,475,477,479,481,483,485,487,489,491,493,495,497,499,501,503,505,507,509],{"id":18,"text":436,"url":18,"identifiers":18},"1. Myers RH, Kiely DK, Cupples LA, Kannel WB (1990) Parental history is an independent risk factor for coronary artery disease: the Framingham Study. Am Heart J 120:963–969.",{"id":18,"text":438,"url":18,"identifiers":18},"2. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U (1994) Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 330:1041–1046.",{"id":18,"text":440,"url":18,"identifiers":18},"3. Erdmann J, Stark K, Esslinger UB et al (2013) Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature 504:432–436.",{"id":18,"text":442,"url":18,"identifiers":18},"4. Goldstein JL, Brown MS (2009) “History of discovery: the LDL receptor”. Arterioscler Thromb Vasc Biol 29:431–438",{"id":18,"text":444,"url":18,"identifiers":18},"5. Kessler T, Vilne B, Schunkert H (2016) The impact of genome- wide association studies on the pathophysiology and therapy of cardiovascular disease. EMBO Mol Med 8:688–701",{"id":18,"text":446,"url":18,"identifiers":18},"6. Samani NJ, Erdmann J, Hall AS, Hengstenberg C et al (2007) WTCCC, Cardiogenics. Genomewide association analysis of coronary artery disease. N Engl J Med 357:443–453",{"id":18,"text":448,"url":18,"identifiers":18},"7. Erdmann J, Grosshennig A, Braund PS et al (2009) New suscep- tibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet 41:280–282.",{"id":18,"text":450,"url":18,"identifiers":18},"8. Schunkert H, Konig IR, Kathiresan S et al (2011). Large-scale association analysis identi es 13 new susceptibility loci for coronary artery disease. Nat Genet 43:333–338.",{"id":18,"text":452,"url":18,"identifiers":18},"9. Nelson CP, Goel A, Butterworth AS et al (2017) Association analyses based on false discovery rate implicate new loci for coronary artery disease. Nat Genet 49:1385–1391.",{"id":18,"text":454,"url":18,"identifiers":18},"10. Van der Harst P, Verweij N (2018) The identication of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. Circ Res 122:433–443.",{"id":18,"text":456,"url":18,"identifiers":18},"11. Erdmann J, Kessler T, Munoz Venegas L, Schunkert H (2018). A decade of genome-wide association studies for coronary artery disease: the challenges ahead. Cardiovasc Res. https:\u002F\u002Fdoi. org\u002F10.1093\u002Fcvr\u002F cvy084.",{"id":18,"text":458,"url":18,"identifiers":18},"12. Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, Yang J (2017) 10 years of GWAS discovery: biology, func- tion, and translation. Am J Hum Genet 101(1):5–22.",{"id":18,"text":460,"url":18,"identifiers":18},"13. Stitziel NO, Stirrups KE, Masca NG et al (2016) Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med 374:1134–1144.",{"id":18,"text":462,"url":18,"identifiers":18},"14. Webb TR, Erdmann J, Stirrups KE et al (2017) Systematic evaluation of pleiotropyidenties 6 further loci associated with coronary artery disease. J Am Coll Cardiol 69:823–836",{"id":18,"text":464,"url":18,"identifiers":18},"15. Schunkert H (2016) Family or SNPs: what counts for hereditary risk of coronary artery disease? Eur Heart J 37:568–571",{"id":18,"text":466,"url":18,"identifiers":18},"16. Braenne I, Kleinecke M, Reiz B et al (2016) Systematic analysis of variants related to familial hypercholesterolemia in families with premature myocardial infarction. Eur J Hum Genet 24:191–197",{"id":18,"text":468,"url":18,"identifiers":18},"17. Stranneheim H, Wedell A (2016) Exome and genome sequenc- ing: a revolution for the discovery and diagnosis of monogenic disorders. J Intern Med 279(1):3–15",{"id":18,"text":470,"url":18,"identifiers":18},"18. Trương Thanh Hương và cs. Phát hiện đột biến gen Fibrinogen beta (FGB) ở một bệnh nhân nhồi máu cơ tim có cơ địa dễ hình thành huyết khối, Y học Việt Nam, 1\u002F2013, tr. 58.",{"id":18,"text":472,"url":18,"identifiers":18},"19. Trương Thanh Hương, Dương Đức Hùng, Nguyễn Thị Mai Ngọc, Lương Thị Lan Anh, Nguyễn Thị Trang. Phát hiện đột biến gen tổng hợp chuỗi nặng beta-myosin (YH7) trong bệnh cơ tim phì đại. Tạp chí Tim mạch học Việt Nam, số 65\u002F2014",{"id":18,"text":474,"url":18,"identifiers":18},"20. Gerald F Watts, Phillip YA Ding, Thanh Huong Truong et al. Translational Research for Improving the Care of Familial Hypercholesterolemia: The “Ten Countries Study” and Beyond. J Atheroscler Thromb, 2016; 23: 891-900. doi: 10.5551\u002Fjat.35949.",{"id":18,"text":476,"url":18,"identifiers":18},"21. Kim Ngọc Thanh, Trần Trung Thành, Trần Đức Huy, Lê Hồng An, Trương Thanh Hương. Nghiên cứu bước đầu về tình trạng bệnh tăng Cholesterol máu có tính chất gia đình ở các trường hợp mắc bệnh ĐMV. Tạp chí tim mạch học Việt Nam – số 81.2018",{"id":18,"text":478,"url":18,"identifiers":18},"22. Nguyễn Thị Thúy Mậu, Vũ Ngọc Trung, Nguyễn Hữu Hiếu, Nguyễn Thanh Thúy, Vũ Thị Thơm, Đinh Đoàn Long, Trịnh Hoàng Hà. Bước đầu đánh giá mối liên quan giữa đa hình gen CYP2C19 và độ ngưng tập tiểu cầu trên bệnh nhân nhồi máu cơ tim cấp tại một số bệnh viện ở Hà Nội. Tạp chí Khoa học ĐHQGHN: Khoa học Y Dược, Tập 33, Số 2 (2017) 68-74",{"id":18,"text":480,"url":18,"identifiers":18},"23. Khera AV, Won HH, Peloso GM, et al (2017) Association of rare and common variation in the",{"id":18,"text":482,"url":18,"identifiers":18},"lipoprotein lipase gene with coronary artery disease. JAMA 7(9):937–946 317.",{"id":18,"text":484,"url":18,"identifiers":18},"24. Ukraintseva S, Yashin A, Arbeev K, Kulminski A, Akushevich I, Wu D, Joshi G, Land KC, Stallard E (2016) Puzzling role of genetic risk factors in human longevity: “risk alleles” as pro-lon- gevity variants. Biogerontology 17(1):109–127",{"id":18,"text":486,"url":18,"identifiers":18},"25. Jansen H, Samani NJ, Schunkert H (2014) Mendelian randomiza- tion studies in coronary artery disease. Eur Heart J 35:1917–1924",{"id":18,"text":488,"url":18,"identifiers":18},"26. Voight BF, Peloso GM, Orho-Melander M, et al (2008) Schunkert HLifelong reduction of LDL- cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease a Mendelian Randomisation study. PLoS One 3:e2986",{"id":18,"text":490,"url":18,"identifiers":18},"27. Linsel-Nitschke P, Götz A, Erdmann J, et al (2008) Schunkert HLifelong reduction of LDL",{"id":18,"text":492,"url":18,"identifiers":18},"-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease a Mendelian Randomisation study. PLoS One 3:e2986",{"id":18,"text":494,"url":18,"identifiers":18},"28. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Floratos A, Sham PC, Li MJ, Wang J, Cardon LR, Whittaker JC, Sanseau P (2015) The support of human genetic evidence for approved drug indications. Nat Genet 47:856–860",{"id":18,"text":496,"url":18,"identifiers":18},"29. Abraham G, Havulinna AS, Bhalala OG, Byars SG, De Livera AM, Yetukuri L, Tikkanen E, Perola M, Schunkert H, Sijbrands EJ, Palotie A, Samani NJ, Salomaa V, Ripatti S, Inouye M (2016) Genomic prediction of coronary heart disease. Eur Heart J 37:3267–3278",{"id":18,"text":498,"url":18,"identifiers":18},"30. International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB, Munroe PB, Rice KM, Bochud M et al. Genetic variants in novel pathways in uence blood pressure and cardiovascular disease risk. Nature 2011; 478(7367):103–109",{"id":18,"text":500,"url":18,"identifiers":18},"31. Morris AP, Voight BF, Teslovich TM, et al. Diabetes Genetics Replication And Meta- analysis (DIAGRAM) Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012;44(9):981–990",{"id":18,"text":502,"url":18,"identifiers":18},"32. Willer CJ, Schmidt EM, Sengupta S, et al (2018) Network analysis of coronary artery disease risk genes elucidates disease mechanisms and druggable targets. Sci Rep 8:3434",{"id":18,"text":504,"url":18,"identifiers":18},"33. Lempiäinen H, Brænne I, Michoel T, et al (2018) Network analysis of coronary artery disease risk genes elucidates disease mechanisms and druggable targets. Sci Rep 8:3434",{"id":18,"text":506,"url":18,"identifiers":18},"34. Braenne I, Civelek M, Vilne B, et al (2015). Prediction of causal candidate genes in coronary artery disease loci. Arterioscler Thromb Vasc Biol 35:2207–2217",{"id":18,"text":508,"url":18,"identifiers":18},"35. Kessler T, Wobst J, Wolf B, et al (2017). Functional characterization of the GUCY1A3 coronary artery disease risk locus. Circulation 136:476–489",{"id":18,"text":510,"url":18,"identifiers":18},"36. Chen CC1, Chen LL, Hsu YT, Liu KJ, Fan CS, Huang TS (2014) The endothelin-integrin axis is involved in macrophage-induced breast cancer cell chemotactic interactions with endothelial cells. J Biol Chem 289:10029–10044.",{"id":512,"createTime":513,"updateTime":514,"relativeEntities":515,"slug":516,"properties":517,"entityType":54,"verifyStatus":55,"verifyTime":513,"verifyNote":56,"syncStatus":17,"languages":527,"translateLanguages":18,"viewCount":19,"primaryUrl":528,"fullTextUrl":529,"authors":530,"publicationType":110,"publisherRelationship":613,"citationCount":19,"citationInfo":632,"publishDate":635,"publishYear":633,"citationAnalyzeStatus":302,"lastCitationAnalyze":636,"indexDatabases":18,"openAccess":18,"references":637,"isForceReanalyzing":152},"aa60ea34-a638-4f44-8324-1347d0680878","2025-02-24T07:45:39.432+00:00","2026-05-16T18:56:52.405+00:00",[],"%C4%90a-h%C3%ACnh-gen-COX-1-kh%C3%A1ng-Aspirin-tr%C3%AAn-b%E1%BB%87nh-nh%C3%A2n-c%C3%B3-b%E1%BB%87nh-%C4%91%E1%BB%99ng-m%E1%BA%A1ch-v%C3%A0nh",{"keywords":518,"gsPaper":519,"abstract":521,"title":523,"doi":525},{},{"VOID":520},"[\"16672803195224172589\"]",{"VI":522},"Tổng quan: Bệnh động mạch vành là nguyên nhân gây tử vong hàng đầu trên thế giới. Kháng aspirin đã được báo cáo trong bệnh lý động mạch vành do ảnh hưởng bởi các đa hình gen Cyclooxygenase-1 (COX-1).\r\nMục tiêu: Xác định tỷ lệ một số đa hình gen COX-1 thường gặp ảnh hưởng đến chuyển hóa aspirin (C-1676T, C644A, G128A, C50T, C22T) và mối liên quan với độ ngưng tập tiểu cầu trên bệnh nhân có bệnh động mạch vành.\r\nPhương pháp: 54 bệnh nhân mắc bệnh động mạch vành điều trị bằng aspirin hàng ngày với liều từ 75-100mg tối thiểu trên 2 tuần được đưa vào nghiên cứu. Hoạt động của aspirin được đánh giá bằng xét nghiệm đo độ ngưng tập tiểu cầu (NTTC) qua chất kết tập ADP.\r\nKết quả: Tần suất của các đa hình C-1676T, C644A, G128A, C22T lần lượt là 81,48%, 14,81%, 3,7% và 3,7%. Đa hình C50T không được tìm thấy. Bệnh nhân mang đa hình C-1676T cho thấy độ ngưng tập tiểu cầu cao hơn với bệnh nhân không mang đi hình gen COX-1 với p= 0,02.\r\nKết luận: Đa hình C-1676T xuất hiện nhiều nhất chiếm 81,48% trong nhóm bệnh nhân có bệnh động mạch vành. Sự xuất hiện của đa hình C-1676T chứng minh làm giảm đáp ứng của aspirin bằng xét nghiệm đo độ ngưng tập tiểu cầu.\r\nTừkhóa: Aspirin, độ NTTC,đa hình gen COX-1.",{"VI":524},"Đa hình gen COX-1 kháng Aspirin trên bệnh nhân có bệnh động mạch vành",{"VOID":526},"10.58354\u002Fjvc.94+95.2021.155",[58],"http:\u002F\u002Fjvc.vnha.org.vn\u002Ftmh\u002Farticle\u002Fview\u002F155","http:\u002F\u002Fjvc.vnha.org.vn\u002Ftmh\u002Farticle\u002Fdownload\u002F155\u002F174",[531,551,564,576,588,600],{"id":532,"sortIndex":19,"researcher":18,"roles":533,"affiliations":534,"properties":548},"0bf7e959-ce76-4965-98dd-a0fed6c73f37",[],[535],{"id":536,"sortIndex":19,"affiliation":537,"properties":545},"4c66641f-9e03-45a3-b801-47a6c87c1a63",{"id":221,"createTime":222,"updateTime":223,"relativeEntities":538,"slug":225,"properties":539,"entityType":76,"verifyStatus":55,"verifyTime":237,"verifyNote":18,"syncStatus":17,"languages":544,"translateLanguages":18,"viewCount":240},[],{"country":540,"title":541,"address":542,"abbreviation":543},{"VOID":228},{"EN":230,"VI":231},{"VI":233,"EN":234},{"VOID":236},[58,239],{"title":546},{"EN":547}," Bác sĩ nội trú, Đại học Y Hà Nội",{"title":549},{"EN":550},"Mạc Thanh Tùng",{"id":552,"sortIndex":30,"researcher":18,"roles":553,"affiliations":554,"properties":561},"a32e9772-7013-4c19-9d3b-6c628ddc2543",[],[555],{"id":556,"sortIndex":19,"affiliation":557,"properties":18},"6b7c8b1e-7e67-4892-ac38-caf018bcadbc",{"id":87,"createTime":88,"updateTime":88,"relativeEntities":558,"slug":90,"properties":559,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":560},{"VI":93},{"title":562},{"EN":563},"Đỗ Doãn Lợi",{"id":565,"sortIndex":28,"researcher":18,"roles":566,"affiliations":567,"properties":574},"2ed67bde-a47f-4acb-906b-a26015037b00",[],[568],{"id":569,"sortIndex":19,"affiliation":570,"properties":18},"8dfc8774-20f7-4888-bee7-9b55b72aa81a",{"id":87,"createTime":88,"updateTime":88,"relativeEntities":571,"slug":90,"properties":572,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":573},{"VI":93},{"title":575},{"EN":96},{"id":577,"sortIndex":203,"researcher":18,"roles":578,"affiliations":579,"properties":586},"a4a2158e-ee34-4d6c-802e-69717f057cdc",[],[580],{"id":581,"sortIndex":19,"affiliation":582,"properties":18},"e3c9e928-4948-4950-ae1d-1f7e80873b41",{"id":87,"createTime":88,"updateTime":88,"relativeEntities":583,"slug":90,"properties":584,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":585},{"VI":93},{"title":587},{"EN":259},{"id":589,"sortIndex":189,"researcher":18,"roles":590,"affiliations":591,"properties":598},"1a52ab4a-0507-4f35-a921-8884a0687a92",[],[592],{"id":593,"sortIndex":19,"affiliation":594,"properties":18},"8607da9e-fda8-473d-9b35-dfd210ec7bfa",{"id":87,"createTime":88,"updateTime":88,"relativeEntities":595,"slug":90,"properties":596,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":597},{"VI":93},{"title":599},{"EN":200},{"id":601,"sortIndex":29,"researcher":18,"roles":602,"affiliations":603,"properties":610},"4abef017-070f-4b9e-ad27-72b3d732ed95",[],[604],{"id":605,"sortIndex":19,"affiliation":606,"properties":18},"73c883ab-b120-4adb-9d3c-ff0adf293d84",{"id":87,"createTime":88,"updateTime":88,"relativeEntities":607,"slug":90,"properties":608,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":609},{"VI":93},{"gsAuthor":611,"title":612},{"VOID":184},{"EN":186},{"url":18,"publisher":614,"properties":627},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":615,"slug":10,"properties":616,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":619,"manageAffiliations":620,"indexDatabases":621,"url":23,"thumbnailPath":18,"statistic":622,"gsStatistic":18,"type":35,"analyzePriority":18},[],{"issn":617,"title":618},{"VOID":13},{"VOID":15},[],[],[],{"impactFactor":19,"impactFactorByYear":623,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":26,"totalPublicationByYear":624,"totalCitation":30,"totalCitationByYear":625,"totalCitationPerPublication":32,"totalCitationPerPublicationByYear":626,"hindexLast5Year":28,"hindex":28},{},{"2015":28,"2016":28,"2018":29,"2019":28,"2021":29,"2022":28,"2023":30},{"2015":28,"2018":28},{"2015":28,"2018":34},{"pages":628,"issue":630},{"VOID":629},"48-57",{"VOID":631},"94+95",{"total":19,"publishYear":633,"statisticByYear":634},2021,{},"2021-01-01","2026-05-16T18:56:52.404+00:00",[638,640,642,644,646,648,650,652,654,656,658,660,662,664,666,668,670,672,674,676,678],{"id":18,"text":639,"url":18,"identifiers":18},"1. Geneva,Switzerlan(2012), CardiovascularDisease:GlobalAtlason Cardiovascular Disease Prevention and Control, World Health Organization.",{"id":18,"text":641,"url":18,"identifiers":18},"2. BhattD.L.,FoxK.A.A.,HackeW.,etal.(2006). Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. N Engl J Med, 354(16), 1706–1717.",{"id":18,"text":643,"url":18,"identifiers":18},"3. KrasopoulosG.,BristerS.J.,BeattieW.S.,etal.(2008). Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ, 336(7637), 195–198.",{"id":18,"text":645,"url":18,"identifiers":18},"4. Lý Tuấn Khải, Quách Hữu Trung và Vũ Điện Biên (2011). Nghiên cứu kháng aspirin ở bệnh nhân bệnh mạch vành dùng aspirin dài ngày. Nghiên cứu Y Học, 15, 358–364.",{"id":18,"text":647,"url":18,"identifiers":18},"5. YokoyamaC.andTanabe T. (1989). Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Commun, 165(2), 888–894.",{"id":18,"text":649,"url":18,"identifiers":18},"6. EikelboomJ.W.,HirshJ.,SpencerF.A.,etal.(2012). Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141(2 Suppl), e89S-e119S.",{"id":18,"text":651,"url":18,"identifiers":18},"7. Arisawa T., Tahara T., Shibata T., et al. (2007). Association between genetic polymorphisms in thecyclooxygenase-1 gene promoter and peptic ulcers in Japan. Int J Mol Med.",{"id":18,"text":653,"url":18,"identifiers":18},"8. Fan L., Cao J., Liu L., et al. (2013). Frequency, Risk Factors, Prognosis, and Genetic Polymorphism of the Cyclooxygenase-1 Gene for Aspirin Resistance in Elderly Chinese Patients with Cardiovascular Disease. Gerontology, 59(2), 122–131.",{"id":18,"text":655,"url":18,"identifiers":18},"9. ZhaoL.,FangJ.,ZhouM.,etal.(2019). Interaction between COX-1 and COX-2 increases susceptibility to ischemic stroke in a Chinese population. BMC Neurol, 19.",{"id":18,"text":657,"url":18,"identifiers":18},"10. XueM.,YangX.,YangL.,etal.(2017). rs5911 and rs3842788 Genetic Polymorphism, Blood Stasis Syndrome, and Plasma TXB2 and hs-CRP Levels Are Associated with Aspirin Resistance in Chinese Chronic Stable Angina Patients. Evid-Based Complement Altern Med ECAM, 2017, 9037094.",{"id":18,"text":659,"url":18,"identifiers":18},"11. Yi X., Cheng W., Lin J., et al. (2016). Interaction between COX-1 and COX-2 Variants Associated with Aspirin Resistance in Chinese Stroke Patients. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc, 25(9), 2136–2144.",{"id":18,"text":661,"url":18,"identifiers":18},"12. Wong K.-C., Zhang J., Yan S., et al. (2013). DNA Sequencing Technologies: Sequencing Data Protocols and Bioinformatics Tools. ACM Comput Surv, 52, 1–30.",{"id":18,"text":663,"url":18,"identifiers":18},"13. NguyễnNgọcMinhvàNguyễnĐìnhÁi. Cầmmáu-Đôngmáuứngdụngvàkỹthuậtvàứngdụngtrong chẩn đoán lâm sàng, Nhà xuất bản Y Học.",{"id":18,"text":665,"url":18,"identifiers":18},"14. NguyễnThịNữ,CungThịTývàĐỗTrungPhấn(1997). Chỉ số ngưng tập tiểu cầu ở người trưởng thành Việt Nam bình thường. Y học Việt Nam, 66–68.",{"id":18,"text":667,"url":18,"identifiers":18},"15. Rocca B. and Petrucci G. (2012). Variability in the Responsiveness to Low-Dose Aspirin: Pharmacological and Disease-Related Mechanisms. Thrombosis, 2012.",{"id":18,"text":669,"url":18,"identifiers":18},"16. KuliczkowskiW.,WitkowskiA.,PolonskiL.,etal.(2009). Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J, 30(4), 426–435.",{"id":18,"text":671,"url":18,"identifiers":18},"17. CYCLOOXYGENASE-1 GENE - SNP - NCBI.",{"id":18,"text":673,"url":18,"identifiers":18},"18. LeeC.R.,BottoneF.G.,KrahnJ.M.,etal. (2007). Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). Pharmacogenet Genomics, 17(2), 145–160.",{"id":18,"text":675,"url":18,"identifiers":18},"19. Maree A.O., Curtin R.J., Chubb A., et al. (2005). Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost, 3(10), 2340–2345.",{"id":18,"text":677,"url":18,"identifiers":18},"v20. WangZ.,ChenY.,HuS.,etal.(2017). A Meta-analysis of the Association of COX-1 Gene rs3842788 and rs1330344 Polymorphism with Aspirin Resistance in Chinese. J Med Diagn Methods, 06(04).",{"id":18,"text":679,"url":18,"identifiers":18},"21. Yi X., Wang C., Zhou Q., et al. (2017). Interaction among COX-2, P2Y1 and GPIIIa gene variants is associated with aspirin resistance and early neurological deterioration in Chinese stroke patients. BMC Neurol, 17(1), 4.",{"id":681,"createTime":682,"updateTime":682,"relativeEntities":683,"slug":684,"properties":685,"entityType":54,"verifyStatus":17,"verifyTime":682,"verifyNote":693,"syncStatus":17,"languages":694,"translateLanguages":18,"viewCount":19,"primaryUrl":695,"fullTextUrl":696,"authors":697,"publicationType":110,"publisherRelationship":754,"citationCount":19,"citationInfo":773,"publishDate":775,"publishYear":131,"citationAnalyzeStatus":302,"lastCitationAnalyze":682,"indexDatabases":18,"openAccess":18,"references":776,"isForceReanalyzing":152},"31d6b358-b52e-4497-9001-a5b9e1d55f1c","2024-11-25T18:33:59.270+00:00",[],"H%C6%B0%E1%BB%9Bng-d%E1%BA%ABn-ch%E1%BA%A9n-%C4%91o%C3%A1n-v%C3%A0-%C4%91i%E1%BB%81u-tr%E1%BB%8B-b%E1%BB%87nh-t%C4%83ng-cholesterol-m%C3%A1u-gia-%C4%91%C3%ACnh-t%E1%BA%A1i-Vi%E1%BB%87t-Nam",{"keywords":686,"gsPaper":687,"abstract":689,"title":691},{},{"VOID":688},"7046060506989924646",{"VI":690},"Bệnh tăng cholesterol máu gia đình (bệnh FH) là bệnh rối loạn chuyển hóa lipid máu di truyền, đặc trưng bởi LDL-C máu tăng cao và bệnh mạch vành sớm. Tại Việt Nam, hiểu biết về bệnh lý này còn hạn chế. Do đó, Viện Tim mạch Việt Nam, Bệnh viện Bạch Mai đưa ra hướng dẫn chẩn đoán và điều trị bệnh FH. Đây là hướng dẫn đầu tiên về bệnh FH tại Việt Nam. Hướng dẫn này nhằm cải thiện chẩn đoán và điều trị bệnh FH tại Việt Nam.\r\nTừ khóa: Tăng cholesterol máu gia đình, chẩn đoán, điều trị.",{"VI":692},"Hướng dẫn chẩn đoán và điều trị bệnh tăng cholesterol máu gia đình tại Việt Nam","Author affiliation is blank",[58],"https:\u002F\u002Fjvc.vnha.org.vn\u002Ftmh\u002Farticle\u002Fview\u002F303","https:\u002F\u002Fjvc.vnha.org.vn\u002Ftmh\u002Farticle\u002Fdownload\u002F303\u002F302",[698,704,716,729,741],{"id":699,"sortIndex":203,"researcher":18,"roles":700,"affiliations":701,"properties":702},"1e7f80d7-5769-4154-90f0-8ade331c23cb",[],[],{"title":703},{"EN":563},{"id":705,"sortIndex":29,"researcher":18,"roles":706,"affiliations":707,"properties":714},"5e521f5d-db4f-4325-9aa8-edc3bc33cd6c",[],[708],{"id":709,"sortIndex":19,"affiliation":710,"properties":18},"4ca8aac6-de8e-42e7-ac57-1afdbf4c64ea",{"id":87,"createTime":88,"updateTime":88,"relativeEntities":711,"slug":90,"properties":712,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":713},{"VI":93},{"title":715},{"EN":259},{"id":717,"sortIndex":30,"researcher":18,"roles":718,"affiliations":719,"properties":726},"feb14f3b-5dab-4329-a0fc-4a0afba73711",[],[720],{"id":721,"sortIndex":19,"affiliation":722,"properties":18},"77e53722-fa63-4f42-8ab3-ddc7a197735b",{"id":87,"createTime":88,"updateTime":88,"relativeEntities":723,"slug":90,"properties":724,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":725},{"VI":93},{"gsAuthor":727,"title":728},{"VOID":184},{"EN":186},{"id":730,"sortIndex":28,"researcher":18,"roles":731,"affiliations":732,"properties":739},"d7832ca9-03e2-4ef0-a1da-1b1b5765495a",[],[733],{"id":734,"sortIndex":19,"affiliation":735,"properties":18},"ad5f5ab5-6429-4ee6-a2b7-694858277f57",{"id":87,"createTime":88,"updateTime":88,"relativeEntities":736,"slug":90,"properties":737,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":738},{"VI":93},{"title":740},{"EN":96},{"id":742,"sortIndex":19,"researcher":18,"roles":743,"affiliations":744,"properties":751},"ec858469-086d-4906-9761-8dc886a4f89f",[],[745],{"id":746,"sortIndex":19,"affiliation":747,"properties":18},"0a05bc2a-e1cf-4e61-b026-6b6cf67b9e82",{"id":87,"createTime":88,"updateTime":88,"relativeEntities":748,"slug":90,"properties":749,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":750},{"VI":93},{"gsAuthor":752,"title":753},{"VOID":413},{"EN":200},{"url":18,"publisher":755,"properties":768},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":756,"slug":10,"properties":757,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":760,"manageAffiliations":761,"indexDatabases":762,"url":23,"thumbnailPath":18,"statistic":763,"gsStatistic":18,"type":35,"analyzePriority":18},[],{"issn":758,"title":759},{"VOID":13},{"VOID":15},[],[],[],{"impactFactor":19,"impactFactorByYear":764,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":26,"totalPublicationByYear":765,"totalCitation":30,"totalCitationByYear":766,"totalCitationPerPublication":32,"totalCitationPerPublicationByYear":767,"hindexLast5Year":28,"hindex":28},{},{"2015":28,"2016":28,"2018":29,"2019":28,"2021":29,"2022":28,"2023":30},{"2015":28,"2018":28},{"2015":28,"2018":34},{"pages":769,"issue":771},{"VOID":770},"5-13",{"VOID":772},"89",{"total":19,"publishYear":131,"statisticByYear":774},{},"2019-09-01",[777,779,781,783,785,787,789,791,793,795,797,799,801,803,805,807,809,811,813,815,817,819,821,823,825,827,829,831,833,835,837],{"id":18,"text":778,"url":18,"identifiers":18},"1. Akioyamen, L.E., et al., Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open, 2017. 7(9): p. e016461.",{"id":18,"text":780,"url":18,"identifiers":18},"2. Vallejo-Vaz, A.J., et al., Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 2018. 277: p. 234-255.",{"id":18,"text":782,"url":18,"identifiers":18},"3. Watts, G.F., et al., Translational Research for Improving the Care of Familial Hypercholesterolemia: The \"Ten Countries Study\" and Beyond. J Atheroscler Thromb, 2016. 23(8): p. 891-900.",{"id":18,"text":784,"url":18,"identifiers":18},"4. Pang, J., et al., An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the \"Ten Countries Study\". BMJ Open, 2017. 7(10): p. e017817.",{"id":18,"text":786,"url":18,"identifiers":18},"5. Pang, J., et al., Comparative aspects of the care of familial hypercholesterolemia in the \"Ten Countries Study\". J Clin Lipidol, 2019. 13(2): p. 287-300.",{"id":18,"text":788,"url":18,"identifiers":18},"6. Truong, T.H., et al., Homozygous familial hypercholesterolaemia in Vietnam: Case series, genetics and cascade testing of families. Atherosclerosis, 2018. 277: p. 392-398.",{"id":18,"text":790,"url":18,"identifiers":18},"7. Harada-Shiba, M., et al., Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017. J Atheroscler Thromb, 2018. 25(8): p. 751-770.",{"id":18,"text":792,"url":18,"identifiers":18},"8. Soutar, A.K. and R.P. Naoumova, Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med, 2007. 4(4): p. 214-25.",{"id":18,"text":794,"url":18,"identifiers":18},"9. Kim Ngọc Thanh, Trần Trung Thành, Trần Đức Huy, Lê Hồng An, Trương Thanh Hương, Nghiên cứu bước đầu về tình trạng bệnh tăng cholesterol máu có tính gia đình ở các trường hợp mắc bệnh mạch vành sớm. Journal of Vietnamese Cardiology. Journal of Vietnamese Cardiology, 2018. 81: p. 33-37.",{"id":18,"text":796,"url":18,"identifiers":18},"10. Starr, B., et al., Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med, 2008. 46(6): p. 791-803.",{"id":18,"text":798,"url":18,"identifiers":18},"11. Cuchel, M., et al., Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J, 2014. 35(32): p. 2146-57.",{"id":18,"text":800,"url":18,"identifiers":18},"12. Wiegman, A., et al., Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. European heart journal, 2015. 36(36): p. 2425-2437.",{"id":18,"text":802,"url":18,"identifiers":18},"13. Li, S., et al., Familial hypercholesterolemia in very young myocardial infarction. Scientific Reports, 2018. 8(1): p. 8861.",{"id":18,"text":804,"url":18,"identifiers":18},"14. Groselj, U., et al., Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review. Atherosclerosis, 2018. 277: p. 383-391.",{"id":18,"text":806,"url":18,"identifiers":18},"15. Klancar, G., et al., Universal Screening for Familial Hypercholesterolemia in Children. J Am Coll Cardiol, 2015. 66(11): p. 1250-1257.",{"id":18,"text":808,"url":18,"identifiers":18},"16. Lazaro, P., et al., Cost-effectiveness of a cascade screening program for the early detection of familia",{"id":18,"text":810,"url":18,"identifiers":18},"hypercholesterolemia. J Clin Lipidol, 2017. 11(1): p. 260-271.",{"id":18,"text":812,"url":18,"identifiers":18},"17. Leren, T.P., et al., Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet, 2008. 11(1): p. 26-35.",{"id":18,"text":814,"url":18,"identifiers":18},"18. Mach, F., et al., 2019 ESC\u002FEAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal, 2019.",{"id":18,"text":816,"url":18,"identifiers":18},"19. Brunham, L.R., et al., Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. Can J Cardiol, 2018. 34(12): p. 1553-1563.",{"id":18,"text":818,"url":18,"identifiers":18},"20. Gagne, C., D. Gaudet, and E. Bruckert, Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation, 2002. 105(21): p. 2469-75.",{"id":18,"text":820,"url":18,"identifiers":18},"21. Menzin, J., et al., Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia. J Manag Care Spec Pharm, 2017. 23(12): p. 1270-1276.",{"id":18,"text":822,"url":18,"identifiers":18},"22. Stein, E.A., et al., Effect of a monoclonal antibody to PCSK9, REGN727\u002FSAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet, 2012. 380(9836): p. 29-36.",{"id":18,"text":824,"url":18,"identifiers":18},"23. Gouni-Berthold, I., et al., Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. 2016. 82(6): p. 1412-1443.",{"id":18,"text":826,"url":18,"identifiers":18},"24. Blaha, M., et al., Pregnancy in homozygous familial hypercholesterolemia-Importance of LDL-apheresis. Atheroscler Suppl, 2015. 18: p. 134-9.",{"id":18,"text":828,"url":18,"identifiers":18},"25. Ogura, M., et al., Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion. Atherosclerosis, 2016. 254: p. 179-183.",{"id":18,"text":830,"url":18,"identifiers":18},"26. Thompson, G.R., et al., Assessment of long-term plasma exchange for familial hypercholesterolaemia. British Heart Journal, 1980. 43(6): p. 680-688.",{"id":18,"text":832,"url":18,"identifiers":18},"27. Martinez, M., et al., Effects of Liver Transplantation on Lipids and Cardiovascular Disease in Children With Homozygous Familial Hypercholesterolemia. Am J Cardiol, 2016. 118(4): p. 504-10.",{"id":18,"text":834,"url":18,"identifiers":18},"28. Kawasuji, M., et al., Coronary artery bypass surgery with arterial grafts in familial hypercholesterolemia. J Thorac Cardiovasc Surg, 2000. 119(5): p. 1008-13; discussion 1013-4.",{"id":18,"text":836,"url":18,"identifiers":18},"29. Nazif, T.M., et al., Percutaneous Coronary Intervention With Bioresorbable Scaffolds in a Young Child. JAMA Cardiol, 2017. 2(4): p. 430-434.",{"id":18,"text":838,"url":18,"identifiers":18},"30. Ravat, H., S. Garekar, and V. Changela, Left Main coronary angioplasty of a 9-year-old child with bioresorbable vascular scaffold [corrected]. Catheter Cardiovasc Interv, 2017. 89(5): p. 867-871.",{"id":840,"createTime":841,"updateTime":842,"relativeEntities":843,"slug":844,"properties":845,"entityType":54,"verifyStatus":55,"verifyTime":841,"verifyNote":56,"syncStatus":17,"languages":858,"translateLanguages":18,"viewCount":19,"primaryUrl":859,"fullTextUrl":860,"authors":861,"publicationType":110,"publisherRelationship":928,"citationCount":19,"citationInfo":947,"publishDate":950,"publishYear":948,"citationAnalyzeStatus":17,"lastCitationAnalyze":951,"indexDatabases":18,"openAccess":18,"references":952,"isForceReanalyzing":152},"2eabdebd-a314-4d82-be50-62bc28576975","2024-10-03T22:24:10.762+00:00","2026-02-02T17:58:33.865+00:00",[],"C%C3%B4ng-ngh%E1%BB%87-gen-v%C3%A0-protein-trong-tim-m%E1%BA%A1ch",{"keywords":846,"gsPaper":848,"abstract":850,"title":853,"doi":856},{"VI":847},"genomics,proteomics,y học chính xác,bệnh tim mạch",{"VOID":849},"3632287464978062405",{"VI":851,"EN":852},"Công nghệ gen và protein đã trở thành thành phần không thể thiếu của y học chính xác, cho quản lý bệnh tim mạch. Những công nghệ tiên tiến này đóng vai trò quan trọng trong việc nâng cao độ chính xác của sàng lọc, phân tầng nguy cơ và phát triển các loại thuốc cũng như phương pháp điều trị chính xác cho các bệnh tim mạch. Dựa trên phân tích dữ liệu genomics và proteomics, chúng ta có thể hiểu biết sâu sắc hơn về cơ chế hình thành và tiến triển của bệnh tim mạch, tạo điều kiện xác định chính xác kiểu hình-kiểu gen của từng cá nhân, từ đó đưa ra các chiến lược dự phòng và điều trị hiệu quả. Ngoài ra, công nghệ gen và protein hứa hẹn sẽ phát triển các loại thuốc mới được thiết kế đặc biệt để nhắm đến các bệnh tim mạch di truyền, phức tạp. Mặc dù có các tiềm năng kể trên, chúng ta vẫn cần phải thận trọng khi áp dụng công nghệ gen và protein trong thực hành quản lý bệnh tim mạch, cân nhắc các yếu tố quan trọng như độ chính xác, chi phí và khả năng tiếp cận. Bài viết này cung cấp cái nhìn toàn diện về các ứng dụng hiện tại và tiềm năng của công nghệ gen và protein trong việc chẩn đoán và điều trị bệnh tim mạch.","Genomic and proteomic technologies have become integral components of precision medicine, revolutionizing the field of cardiovascular disease management. These advanced technologies play a crucial role in enhancing screening accuracy, risk stratification, and the development of precise drugs and treatments for heart-related diseases. By leveraging gene and protein profile data, these technologies enable a more profound understanding of cardiovascular diseases, leading to more effective prevention and treatment strategies. Moreover, they facilitate the identification of individual genotype-phenotype differences, allowing for the creation of tailored cardiovascular prevention plans. Additionally, gene and protein technology holds promise in the development of novel drugs specifically designed to target complex, genetic cardiovascular diseases. However, it is important to exercise caution when applying gene and protein technology in cardiology, considering factors such as accuracy, cost, and accessibility. This article provides a comprehensive overview of the current and potential applications of gene and protein technology in managing and improving cardiovascular disease outcomes.",{"VI":854,"EN":855},"Công nghệ gen và protein trong tim mạch","Genomic and proteomic technologies in cardiology",{"VOID":857},"10.58354\u002Fjvc.107S(1).2024.778",[58],"https:\u002F\u002Fjvc.vnha.org.vn\u002Ftmh\u002Farticle\u002Fview\u002F778","https:\u002F\u002Fjvc.vnha.org.vn\u002Ftmh\u002Farticle\u002Fdownload\u002F778\u002F694",[862,882,899],{"id":863,"sortIndex":19,"researcher":18,"roles":864,"affiliations":865,"properties":878},"7c275fce-cf77-4f16-902a-51de623b4ecb",[],[866],{"id":867,"sortIndex":19,"affiliation":868,"properties":876},"1f5c6de9-c705-47e9-93dd-93eb283935de",{"id":221,"createTime":222,"updateTime":223,"relativeEntities":869,"slug":225,"properties":870,"entityType":76,"verifyStatus":55,"verifyTime":237,"verifyNote":18,"syncStatus":17,"languages":875,"translateLanguages":18,"viewCount":240},[],{"country":871,"title":872,"address":873,"abbreviation":874},{"VOID":228},{"EN":230,"VI":231},{"VI":233,"EN":234},{"VOID":236},[58,239],{"title":877},{"EN":231},{"gsAuthor":879,"title":880},{"VOID":184},{"EN":881},"Ngọc Thanh Kim",{"id":883,"sortIndex":30,"researcher":18,"roles":884,"affiliations":885,"properties":896},"b53f9027-9d99-4cbc-9c19-c4d975cc905c",[],[886],{"id":887,"sortIndex":19,"affiliation":888,"properties":893},"09df9362-300a-45c0-89ce-28d4a45c349a",{"id":372,"createTime":373,"updateTime":374,"relativeEntities":889,"slug":376,"properties":890,"entityType":76,"verifyStatus":55,"verifyTime":382,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":26},[],{"country":891,"title":892},{"VOID":228},{"EN":380,"VI":381},{"title":894},{"EN":895},"Viện Tim mạch Việt Nam, Bệnh viện Bạch Mai",{"title":897},{"EN":898},"Lân Việt Nguyễn",{"id":900,"sortIndex":28,"researcher":18,"roles":901,"affiliations":902,"properties":924},"cedf4dc7-a7c5-4cf5-8cb4-58c2d77672d8",[],[903],{"id":904,"sortIndex":19,"affiliation":905,"properties":922},"67b2841d-652d-473b-a038-163b2dfd4014",{"id":906,"createTime":907,"updateTime":908,"relativeEntities":909,"slug":910,"properties":911,"entityType":76,"verifyStatus":55,"verifyTime":921,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":240},"4c6821f1-29d5-4d67-b05a-f710bb206326","2023-07-03T07:15:37.973+00:00","2026-06-19T02:30:16.552+00:00",[],"Tr%C6%B0%E1%BB%9Dng-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Phenikaa",{"country":912,"title":913,"abbreviation":916,"address":918},{"VOID":228},{"EN":914,"VI":915},"Phenikaa University","Trường Đại học Phenikaa",{"VOID":917},"Phenikaa",{"VI":919,"EN":920},"Số 167 đường Tố Hữu, Phường Yên Nghĩa, Quận Hà Đông, Hà Nội, Việt Nam","No. 167 To Huu Street, Yen Nghia Ward, Ha Dong District, Hanoi, Vietnam","2023-08-16T11:07:26.864+00:00",{"title":923},{"EN":915},{"gsAuthor":925,"title":926},{"VOID":413},{"EN":927},"Thanh Hương Trương",{"url":18,"publisher":929,"properties":942},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":930,"slug":10,"properties":931,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":934,"manageAffiliations":935,"indexDatabases":936,"url":23,"thumbnailPath":18,"statistic":937,"gsStatistic":18,"type":35,"analyzePriority":18},[],{"issn":932,"title":933},{"VOID":13},{"VOID":15},[],[],[],{"impactFactor":19,"impactFactorByYear":938,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":26,"totalPublicationByYear":939,"totalCitation":30,"totalCitationByYear":940,"totalCitationPerPublication":32,"totalCitationPerPublicationByYear":941,"hindexLast5Year":28,"hindex":28},{},{"2015":28,"2016":28,"2018":29,"2019":28,"2021":29,"2022":28,"2023":30},{"2015":28,"2018":28},{"2015":28,"2018":34},{"pages":943,"issue":945},{"VOID":944},"",{"VOID":946},"107S(1)",{"total":19,"publishYear":948,"statisticByYear":949},2024,{},"2024-01-20","2026-02-02T17:58:33.864+00:00",[953,955,957,959,961,963,965,967,969,971,973,975,977,979,981,983,985,987,989,991,993,995,997],{"id":18,"text":954,"url":18,"identifiers":18},"Antman EM, Loscalzo J. Precision medicine in cardiology. Nat Rev Cardiol. 2016;13(10):591-602. doi:10.1038\u002Fnrcardio.2016.101",{"id":18,"text":956,"url":18,"identifiers":18},"Li C, Pan Y, Zhang R, et al. Genomic Innovation in Early Life Cardiovascular Disease Prevention and Treatment. Circ Res. 2023;132(12):1628-1647. doi:10.1161\u002FCIRCRESAHA.123.321999",{"id":18,"text":958,"url":18,"identifiers":18},"Mokou M, Lygirou V, Vlahou A, Mischak H. Proteomics in cardiovascular disease: recent progress and clinical implication and implementation. Expert Rev Proteomics. 2017;14(2):117-136. doi:10.1080\u002F14789450.2017.1274653",{"id":18,"text":960,"url":18,"identifiers":18},"Leopold JA, Loscalzo J. Emerging Role of Precision Medicine in Cardiovascular Disease. Circ Res. 2018;122(9):1302-1315. doi:10.1161\u002FCIRCRESAHA.117.310782",{"id":18,"text":962,"url":18,"identifiers":18},"O'Sullivan JW, Raghavan S, Marquez-Luna C, et al. Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2022;146(8):e93-e118. doi:10.1161\u002FCIR.0000000000001077",{"id":18,"text":964,"url":18,"identifiers":18},"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice [published correction appears in Eur Heart J. 2022;43(42):4468]. Eur Heart J. 2021;42(34):3227-3337. doi:10.1093\u002Feurheartj\u002Fehab484",{"id":18,"text":966,"url":18,"identifiers":18},"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC\u002FAHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\u002FAmerican Heart Association Task Force on Clinical Practice Guidelines [published correction appears in Circulation. 2019;140(11):e649-e650] [published correction appears in Circulation. 2020;141(4):e60] [published correction appears in Circulation. 2020;141(16):e774]. Circulation. 2019;140(11):e596-e646. doi:10.1161\u002FCIR.0000000000000678",{"id":18,"text":968,"url":18,"identifiers":18},"Sopic M, Vilne B, Gerdts E, et al. Multiomics tools for improved atherosclerotic cardiovascular disease management. Trends Mol Med. 2023;29(12):983-995. doi:10.1016\u002Fj.molmed.2023.09.004",{"id":18,"text":970,"url":18,"identifiers":18},"Musunuru K, Hershberger RE, Day SM, et al. Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association. Circ Genom Precis Med. 2020;13(4):e000067. doi:10.1161\u002FHCG.0000000000000067",{"id":18,"text":972,"url":18,"identifiers":18},"Nurmohamed NS, Kraaijenhof JM, Mayr M, et al. Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction. Eur Heart J. 2023;44(18):1594-1607. doi:10.1093\u002Feurheartj\u002Fehad161",{"id":18,"text":974,"url":18,"identifiers":18},"Haslam DE, Li J, Dillon ST, et al. Stability and reproducibility of proteomic profiles in epidemiological studies: comparing the Olink and SOMAscan platforms. Proteomics. 2022;22(13-14):e2100170. doi:10.1002\u002Fpmic.202100170",{"id":18,"text":976,"url":18,"identifiers":18},"Ganz P, Heidecker B, Hveem K, et al. Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease. JAMA. 2016;315(23):2532-2541. doi:10.1001\u002Fjama.2016.5951",{"id":18,"text":978,"url":18,"identifiers":18},"Williams SA, Ostroff R, Hinterberg MA, et al. A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk. Sci Transl Med. 2022;14(639):eabj9625. doi:10.1126\u002Fscitranslmed.abj9625",{"id":18,"text":980,"url":18,"identifiers":18},"Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet. 2020;396(10253):758]. Lancet. 2020;396(10253):759-769. doi:10.1016\u002FS0140-6736(20)31792-X",{"id":18,"text":982,"url":18,"identifiers":18},"Schmidt AF, Carter JL, Pearce LS, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020;10(10):CD011748. doi:10.1002\u002F14651858.CD011748.pub3",{"id":18,"text":984,"url":18,"identifiers":18},"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107. doi:10.1056\u002FNEJMoa1801174",{"id":18,"text":986,"url":18,"identifiers":18},"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056\u002FNEJMoa1615664",{"id":18,"text":988,"url":18,"identifiers":18},"Zhang H, Liao M, Cao M, et al. ATRQβ-001 Vaccine Prevents Experimental Abdominal Aortic Aneurysms. J Am Heart Assoc. 2019;8(18):e012341. doi:10.1161\u002FJAHA.119.012341",{"id":18,"text":990,"url":18,"identifiers":18},"Dai Y, Chen X, Song X, et al. Immunotherapy of Endothelin-1 Receptor Type A for Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2019;73(20):2567-2580. doi:10.1016\u002Fj.jacc.2019.02.067",{"id":18,"text":992,"url":18,"identifiers":18},"Zhao Z, Chen Y, Francisco NM, et al. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018;8(4):539-551. doi:10.1016\u002Fj.apsb.2018.03.001",{"id":18,"text":994,"url":18,"identifiers":18},"Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056\u002FNEJMoa1912387",{"id":18,"text":996,"url":18,"identifiers":18},"Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9719):998-1006. doi:10.1016\u002FS0140-6736(10)60284-X",{"id":18,"text":998,"url":18,"identifiers":18},"Liu N, Olson EN. CRISPR Modeling and Correction of Cardiovascular Disease. Circ Res. 2022;130(12):1827-1850. doi:10.1161\u002FCIRCRESAHA.122.320496",{"id":1000,"createTime":1001,"updateTime":1002,"relativeEntities":1003,"slug":1004,"properties":1005,"entityType":54,"verifyStatus":55,"verifyTime":1012,"verifyNote":56,"syncStatus":17,"languages":1013,"translateLanguages":18,"viewCount":19,"primaryUrl":1014,"fullTextUrl":1015,"authors":1016,"publicationType":110,"publisherRelationship":1068,"citationCount":19,"citationInfo":1087,"publishDate":1089,"publishYear":1090,"citationAnalyzeStatus":17,"lastCitationAnalyze":1091,"indexDatabases":18,"openAccess":18,"references":1092,"isForceReanalyzing":152},"21e40155-6a7f-4d59-96d1-6d0caadf3fe6","2024-04-20T10:22:10.611+00:00","2026-05-17T17:55:05.755+00:00",[],"Vai-tr%C3%B2-si%C3%AAu-%C3%A2m-Doppler-tim-trong-h%C6%B0%E1%BB%9Bng-d%E1%BA%ABn-l%E1%BA%ADp-tr%C3%ACnh-t%E1%BB%91i-%C6%B0u-h%C3%B3a-m%C3%A1y-t%E1%BA%A1o-nh%E1%BB%8Bp-t%C3%A1i-%C4%91%E1%BB%93ng-b%E1%BB%99-c%C6%A1-tim-crt-%E1%BB%9F-c%C3%A1c-b%E1%BB%87nh-nh%C3%A2n-suy-tim-n%E1%BA%B7ng-theo-ph%C6%B0%C6%A1ng-ph%C3%A1p-t%E1%BB%91i-%C6%B0u-h%C3%B3a-th%E1%BB%9Di-gian-d%E1%BA%ABn-truy%E1%BB%81n-gi%E1%BB%AFa-hai-th%E1%BA%A5t",{"keywords":1006,"gsPaper":1007,"abstract":1009,"title":1011},{},{"VOID":1008},"6209631108979484836",{"VI":1010},"Vai trò siêu âm Doppler tim trong hướng dẫn lập trình tối ưu hóa máy tạo nhịp tái đồng bộ cơ tim (crt) ở các bệnh nhân suy tim nặng theo phương pháp tối ưu hóa thời gian dẫn truyền giữa hai thất",{"VI":1010},"2025-01-07T02:45:20.697+00:00",[58],"https:\u002F\u002Fjvc.vnha.org.vn\u002Ftmh\u002Farticle\u002Fview\u002F576","https:\u002F\u002Fjvc.vnha.org.vn\u002Ftmh\u002Farticle\u002Fdownload\u002F576\u002F548",[1017,1030,1043,1055],{"id":1018,"sortIndex":29,"researcher":18,"roles":1019,"affiliations":1020,"properties":1027},"6ba358a1-9230-475d-9381-06811c86e40a",[],[1021],{"id":1022,"sortIndex":19,"affiliation":1023,"properties":18},"38767fea-cf7f-4991-8320-3670d1a1dce2",{"id":87,"createTime":88,"updateTime":88,"relativeEntities":1024,"slug":90,"properties":1025,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1026},{"VI":93},{"title":1028},{"EN":1029},"Đỗ Kim Bảng",{"id":1031,"sortIndex":19,"researcher":18,"roles":1032,"affiliations":1033,"properties":1040},"e3fb5f60-5071-45b1-9cbb-763ced1a2e60",[],[1034],{"id":1035,"sortIndex":19,"affiliation":1036,"properties":18},"a5e3071d-ed36-467f-9cf4-f94b8476744d",{"id":87,"createTime":88,"updateTime":88,"relativeEntities":1037,"slug":90,"properties":1038,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1039},{"VI":93},{"gsAuthor":1041,"title":1042},{"VOID":413},{"EN":200},{"id":1044,"sortIndex":30,"researcher":18,"roles":1045,"affiliations":1046,"properties":1053},"6476d564-6530-4d10-aa1e-22d0b2129dd0",[],[1047],{"id":1048,"sortIndex":19,"affiliation":1049,"properties":18},"746bdb78-787f-44a2-a0dd-e65afa435542",{"id":87,"createTime":88,"updateTime":88,"relativeEntities":1050,"slug":90,"properties":1051,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1052},{"VI":93},{"title":1054},{"EN":96},{"id":1056,"sortIndex":28,"researcher":18,"roles":1057,"affiliations":1058,"properties":1065},"3c730727-d3ef-4374-bfdc-8a342475e208",[],[1059],{"id":1060,"sortIndex":19,"affiliation":1061,"properties":18},"eae6bf4a-6e76-4b03-8b07-0d599dcaf791",{"id":87,"createTime":88,"updateTime":88,"relativeEntities":1062,"slug":90,"properties":1063,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1064},{"VI":93},{"title":1066},{"EN":1067},"Phạm Như Hùng",{"url":18,"publisher":1069,"properties":1082},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1070,"slug":10,"properties":1071,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1074,"manageAffiliations":1075,"indexDatabases":1076,"url":23,"thumbnailPath":18,"statistic":1077,"gsStatistic":18,"type":35,"analyzePriority":18},[],{"issn":1072,"title":1073},{"VOID":13},{"VOID":15},[],[],[],{"impactFactor":19,"impactFactorByYear":1078,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":26,"totalPublicationByYear":1079,"totalCitation":30,"totalCitationByYear":1080,"totalCitationPerPublication":32,"totalCitationPerPublicationByYear":1081,"hindexLast5Year":28,"hindex":28},{},{"2015":28,"2016":28,"2018":29,"2019":28,"2021":29,"2022":28,"2023":30},{"2015":28,"2018":28},{"2015":28,"2018":34},{"pages":1083,"issue":1085},{"VOID":1084},"46-53",{"VOID":1086},"69",{"total":19,"publishYear":19,"statisticByYear":1088},{},"2015-04-01",2015,"2026-05-17T17:55:05.754+00:00",[1093,1095,1097,1099,1101,1103],{"id":18,"text":1094,"url":18,"identifiers":18},"1. Wilkerson Group Survey, 1998. Congestive heart failure worldwilde market, clinical status and product development. New medcine, Inc. 1997: 1-40.",{"id":18,"text":1096,"url":18,"identifiers":18},"2. Phạm Việt Tuân và cộng sự. Luận văn tốt nghiệp cao học 2009.",{"id":18,"text":1098,"url":18,"identifiers":18},"3. Boriani G, Muller CP, Seidl KH et al (2006); Resynchronization for the HemodYnamic Treatment for Heart Failure Management II Investigators. Randomized comparison of simultaneous biventricular stimulation versus optimized interventricular delay in cardiac resynchronization therapy. The Resynchronization for the HemodYnamic Treatment for Hear t Fai lure Management I I implantable cardioverter defi brillator (RHYTHM II ICD) study. Am Heart J 2006; 151: 1050–1058.",{"id":18,"text":1100,"url":18,"identifiers":18},"4. Baker JH, McKenzie J, Beau S et al (2007). Acute evaluation of programmer-guided AV\u002FPV and VV delay optimization comparing an IEGM method and echocardiogram for cardiac resynchronization therapy in heart failure patients and dual-chamber ICD implants. J Cardiovasc Electrophysiol 2007; 18: 185–191.",{"id":18,"text":1102,"url":18,"identifiers":18},"5. Stanton T, Hawkins NM, Hogg KJ, Goodfield NE, Petrie MC, McMurray JJ. How should we optimize cardiac resynchronization therapy? Eur Heart J. 2008 Oct;29(20):2458-72.",{"id":18,"text":1104,"url":18,"identifiers":18},"6. Ypenburg C, Van De Veire N, Westenberg JJ, Bleeker GB, Marsan NA, Henneman MM, Van Der Wall EE, Schalij MJ, Abraham TP, Barold SS, Bax JJ.Noninvasive imaging in cardiac resynchronization therapy--Part 2: Follow-up and optimization of settings. Pacing Clin Electrophysiol. 2008 Dec;31(12):1628-39.",{"id":1106,"createTime":1107,"updateTime":1108,"relativeEntities":1109,"slug":1110,"properties":1111,"entityType":54,"verifyStatus":55,"verifyTime":1120,"verifyNote":56,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1121,"fullTextUrl":18,"authors":1122,"publicationType":110,"publisherRelationship":1253,"citationCount":19,"citationInfo":1272,"publishDate":432,"publishYear":430,"citationAnalyzeStatus":17,"lastCitationAnalyze":1274,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":152},"a7073a64-1272-4cbd-a5ff-34f5ba90356b","2024-01-22T18:38:33.333+00:00","2026-05-12T16:44:08.269+00:00",[],"Can-thi%E1%BB%87p-Tim-b%E1%BA%A9m-sinh-t%E1%BA%A1i-Vi%E1%BB%87n-Tim-m%E1%BA%A1ch-Vi%E1%BB%87t-Nam-B%E1%BB%87nh-vi%E1%BB%87n-B%E1%BA%A1ch-Mai-k%E1%BA%BFt-qu%E1%BA%A3-sau-2-n%C4%83m-nh%C3%ACn-l%E1%BA%A1i-2015-2016",{"references":1112,"gsPaper":1114,"abstract":1116,"title":1118},{"VOID":1113},"1. Theo Vos, Ryan M. Barber, Brad Bell và các cộng sự., \"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013\", The Lancet, 386(9995), tr. 743-800.\n2. Ariane J. Marelli, Raluca Ionescu-Ittu, Andrew S. Mackie và các cộng sự. (2014), \"Lifetime Prevalence of Congenital Heart Disease in the General Population From 2000 to 2010\", Circulation, 130(9), tr. 749-756.\n3. Yumi Shiina, Tomohiko Toyoda, Yasutaka Kawasoe và các cộng sự., \"Prevalence of adult patients with congenital heart disease in Japan\", International Journal of Cardiology, 146(1), tr. 13-16.\n4. Nguyễn Lân Việt (2010 ), \"nghiên cứu mô hình bệnh tạt ở bệnh nhân điều trị nội trú tại Viện Tim Mạch Việt Nam trong thời gian 2003-2007\", Tạp chí Tim mạch học số 52.\n5. Phạm Mạnh Hùng: can thiệp tim bẩm sinh: làm gì? bao giờ? khi nào.\n6. Carianne L. Verheugt, Cuno S.P.M. Uiterwaal, Enno T. van der Velde và các cộng sự. (2008), \"Gender and Outcome in Adult Congenital Heart Disease\", Circulation, 118(1), tr. 26-32.\n7. Lê Thành Khánh Vân (2015), \"Điều trị bệnh tim bẩm sinh tại bệnh viện Chợ Rẫy \", Tạp chí y học thực hành.\n8. P. Engelfriet và B. Mulder (2009), \"Gender differences in adult congenital heart disease\", Neth Heart J, 17(11), tr. 414-7.\n9. Nguyễn Thị Nhung (2016): Nhận xét đặc điểm tim bẩm sinh người lớn tại Viện Tim mạch quốc gia- Luận văn tốt nghiệp BS đa khoa 2016.\n10. Nelson textbook of pediatrics 20th (Daniel Bernstein,), Elsevier.\n11. Trần Thị Mai Hồng (2012), \"Nghiên cứu sự thay đổi các chỉ số huyết học ở bệnh nhân tim bẩm sinh.\",\nLuận văn tốt nghiệp bác sĩ đa khoa.\n12. Lê Thị Kim Dung, \"Phân loại tim bẩm sinh điều trị tại khoa Nhi bệnh viện Đa khoa Thái Nguyên. \".\n13. Nguyễn Thị Thanh Hương (2010), \"Đặc điểm bệnh lý tim bẩm sinh ở trẻ sơ sinh tại Bệnh viện Nhi đồng 1. \", Tạp chí y học thành phố Hồ Chí Minh.\n14. Ths.Bs. Hoàng Thị Phú Bằng và cộng sự (2017): Can thiệp bằng ống thông ở bệnh nhân Tim bẩm sinh: nghiên cứu hồi cứu tại Việt Nam, báo cáo hội nghị can thiệp tim mạch toàn quốc 11\u002F2017 tại Cần thơ.",{"VOID":1115},"3797842079972816911",{"VI":1117},"Giới thiệu: Số lượng bệnh nhân mắc tim bẩm sinh được can thiệp bằng đường ống thông ngày càng tăng ở Việt Nam.\r\nMục tiêu: Nghiên cứu chúng tôi nhằm báo cáo kết quả, hiệu quả và biến chứng can thiệp bằng ống thông cho bệnh nhân tim bẩm sinh tại Viện Tim mạch Việt Nam 2015-2016.\r\nPhương pháp: Chúng tôi tuyển chọn 1265 bệnh nhân (tuổi trung bình: 25,8 ± 17.0; nhỏ nhất 6 tháng tuổi, cao nhất 76 tuổi) có bệnh tim bẩm sinh mà được thực hiện can thiệp qua da từ tháng 1\u002F2015 đến tháng 12\u002F2016. Toàn bộ dữ liệu lâm sàng được thu thập hồi cứu dựa trên dữ liệu bệnh viện và bệnh án bệnh nhân.\r\nKết quả: Nghiên cứu của chúng tôi ghi nhận gồm 1265 ca can thiệp TBS\u002F22.416 ca nhập viện nội trú (5,64%), trong đó chủ yếu là thông liên nhĩ (TLN), thông liên thất (TLT) và ống động mạch (ÔĐM), cụ thể như sau: 499 ca TLN (39,6%), 158 ca TLT (12,5%), 251 ca CODM (19.8%), 52 ca hẹp van động mạch phổi và 7 ca nong van ĐMC.\r\nThủ thuật can thiệp thành công trên 1194\u002F1265 ca (94,4%). Biến chứng sớm chính xảy ra ở 71 ca (5,6%), trong đó bao gồm 52 ca rối loạn nhịp, 10 ca đái máu, 1 ca ép tim do tràn máu màng ngoài tim cấp và 2 ca di lệch dụng cụ (1 TLT, 1 TLN). Biến chứng khác là shunt tồn lưu nhỏ ở 6 ca TLT, TLN. Thời gian theo dõi sau can thiệp là 3 ngày. Chúng tôi không ghi nhận tắc mạch não, nhồi máu cơ tim, và tử vong trong quá trình can thiệp cũng như thời gian theo dõi.\r\nKết luận: Phương pháp can thiệp bằng ống thông theo đường dưới da cho bệnh nhân tim bẩm sinh là hiệu quả và an toàn trong đại đa số các ca. Tỷ lệ biến chứng sớm sau can thiệp là 5,6%.\r\nTừ khóa: Bệnh tim bẩm sinh, biến chứng sớm sau can thiệp, can thiệp tim bẩm sinh.",{"VI":1119},"Can thiệp Tim bẩm sinh tại Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai: kết quả sau 2 năm nhìn lại 2015-2016","2025-01-18T03:57:24.429+00:00","https:\u002F\u002Fjvc.vnha.org.vn\u002Ftmh\u002Farticle\u002Fview\u002F426",[1123,1136,1147,1167,1179,1191,1203,1216,1228,1241],{"id":1124,"sortIndex":189,"researcher":18,"roles":1125,"affiliations":1127,"properties":1133},"cec448bc-c6a1-4b8e-9bf8-90461aec3ab5",[1126],"AUTHOR",[1128],{"id":18,"sortIndex":19,"affiliation":1129,"properties":18},{"id":87,"createTime":88,"updateTime":88,"relativeEntities":1130,"slug":90,"properties":1131,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1132},{"VI":93},{"title":1134},{"VI":1135},"Trần Bảo Trang",{"id":1137,"sortIndex":19,"researcher":18,"roles":1138,"affiliations":1139,"properties":1145},"ece7dd0c-e87a-4c11-8929-3da3fe21cea5",[1126],[1140],{"id":18,"sortIndex":19,"affiliation":1141,"properties":18},{"id":87,"createTime":88,"updateTime":88,"relativeEntities":1142,"slug":90,"properties":1143,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1144},{"VI":93},{"title":1146},{"VI":96},{"id":1148,"sortIndex":1149,"researcher":18,"roles":1150,"affiliations":1151,"properties":1164},"ad2f0c85-f4ee-437b-aec4-6e9449cb5e86",8,[1126],[1152],{"id":1153,"sortIndex":19,"affiliation":1154,"properties":1162},"5ece4c1f-32a2-402b-9aa3-8d3e98c97705",{"id":221,"createTime":222,"updateTime":223,"relativeEntities":1155,"slug":225,"properties":1156,"entityType":76,"verifyStatus":55,"verifyTime":237,"verifyNote":18,"syncStatus":17,"languages":1161,"translateLanguages":18,"viewCount":240},[],{"country":1157,"title":1158,"address":1159,"abbreviation":1160},{"VOID":228},{"EN":230,"VI":231},{"VI":233,"EN":234},{"VOID":236},[58,239],{"title":1163},{"EN":276},{"title":1165},{"VI":1166},"Nguyễn Lân Hiếu",{"id":1168,"sortIndex":28,"researcher":18,"roles":1169,"affiliations":1170,"properties":1176},"0a752b0f-94e2-4e95-bd99-7efa0de382c9",[1126],[1171],{"id":18,"sortIndex":19,"affiliation":1172,"properties":18},{"id":87,"createTime":88,"updateTime":88,"relativeEntities":1173,"slug":90,"properties":1174,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1175},{"VI":93},{"gsAuthor":1177,"title":1178},{"VOID":184},{"VI":186},{"id":1180,"sortIndex":1181,"researcher":18,"roles":1182,"affiliations":1183,"properties":1189},"b3eaafcb-2511-4fb0-ad74-0f5871e30647",9,[1126],[1184],{"id":18,"sortIndex":19,"affiliation":1185,"properties":18},{"id":87,"createTime":88,"updateTime":88,"relativeEntities":1186,"slug":90,"properties":1187,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1188},{"VI":93},{"title":1190},{"VI":200},{"id":1192,"sortIndex":30,"researcher":18,"roles":1193,"affiliations":1194,"properties":1200},"8523ac4c-da7b-4de4-80b4-67f2b5fcf94a",[1126],[1195],{"id":18,"sortIndex":19,"affiliation":1196,"properties":18},{"id":87,"createTime":88,"updateTime":88,"relativeEntities":1197,"slug":90,"properties":1198,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1199},{"VI":93},{"gsAuthor":1201,"title":1202},{"VOID":399},{"VI":401},{"id":1204,"sortIndex":1205,"researcher":18,"roles":1206,"affiliations":1207,"properties":1213},"65667a2e-7f82-4cbd-848e-9da1527cd73e",6,[1126],[1208],{"id":18,"sortIndex":19,"affiliation":1209,"properties":18},{"id":87,"createTime":88,"updateTime":88,"relativeEntities":1210,"slug":90,"properties":1211,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1212},{"VI":93},{"title":1214},{"VI":1215},"Đỗ Quốc Hiển",{"id":1217,"sortIndex":203,"researcher":18,"roles":1218,"affiliations":1219,"properties":1225},"a538149e-b8ef-4609-906b-4f2e8efcd2c8",[1126],[1220],{"id":18,"sortIndex":19,"affiliation":1221,"properties":18},{"id":87,"createTime":88,"updateTime":88,"relativeEntities":1222,"slug":90,"properties":1223,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1224},{"VI":93},{"title":1226},{"VI":1227},"Nguyễn Minh Hùng",{"id":1229,"sortIndex":1230,"researcher":18,"roles":1231,"affiliations":1232,"properties":1238},"d1602e20-bd90-48a7-962b-7752268c189a",7,[1126],[1233],{"id":18,"sortIndex":19,"affiliation":1234,"properties":18},{"id":87,"createTime":88,"updateTime":88,"relativeEntities":1235,"slug":90,"properties":1236,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1237},{"VI":93},{"title":1239},{"VI":1240},"Phạm Tuấn Việt",{"id":1242,"sortIndex":29,"researcher":18,"roles":1243,"affiliations":1244,"properties":1250},"1093a8d3-e5a3-4625-8c48-f3fe1c0082c1",[1126],[1245],{"id":18,"sortIndex":19,"affiliation":1246,"properties":18},{"id":87,"createTime":88,"updateTime":88,"relativeEntities":1247,"slug":90,"properties":1248,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1249},{"VI":93},{"title":1251},{"VI":1252},"Đỗ Thu Trang",{"url":1121,"publisher":1254,"properties":1267},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1255,"slug":10,"properties":1256,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1259,"manageAffiliations":1260,"indexDatabases":1261,"url":23,"thumbnailPath":18,"statistic":1262,"gsStatistic":18,"type":35,"analyzePriority":18},[],{"issn":1257,"title":1258},{"VOID":13},{"VOID":15},[],[],[],{"impactFactor":19,"impactFactorByYear":1263,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":26,"totalPublicationByYear":1264,"totalCitation":30,"totalCitationByYear":1265,"totalCitationPerPublication":32,"totalCitationPerPublicationByYear":1266,"hindexLast5Year":28,"hindex":28},{},{"2015":28,"2016":28,"2018":29,"2019":28,"2021":29,"2022":28,"2023":30},{"2015":28,"2018":28},{"2015":28,"2018":34},{"pages":1268,"issue":1270},{"VOID":1269},"145-152",{"VOID":1271},"84+85",{"total":19,"publishYear":19,"statisticByYear":1273},{},"2026-05-12T16:44:08.268+00:00",{"id":1276,"createTime":1277,"updateTime":1277,"relativeEntities":1278,"slug":1279,"properties":1280,"entityType":54,"verifyStatus":17,"verifyTime":1288,"verifyNote":693,"syncStatus":17,"languages":1289,"translateLanguages":18,"viewCount":19,"primaryUrl":1290,"fullTextUrl":18,"authors":1291,"publicationType":110,"publisherRelationship":1348,"citationCount":18,"citationInfo":18,"publishDate":1368,"publishYear":1369,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":1370,"openAccess":18,"references":1371,"isForceReanalyzing":152},"f0ebce22-4447-4f8f-9b5b-65a6ccdf793c","2026-06-17T15:29:55.808+00:00",[],"Assessment-of-left-ventricular-systolic-function-in-patients-with-chronic-coronary-syndrome-and-heart-failure-with-reduced-ejection-fraction-after-percutaneous-coronary-intervention",{"keywords":1281,"abstract":1282,"title":1284,"doi":1286},{},{"VI":1283},"Objective: Describe the characteristic and change of left ventricular systolic function after percutaneous coronary intervention in patients with chronic coronary syndrome and heart failure with reduced ejection fraction after percutaneous coronary intervention. Methods: This prospective study involved the monitoring of 40 patients who had an ejection fraction of 40% or less and were diagnosed with chronic coronary artery disease. These patients underwent a successful percutaneous coronary intervention at the Vietnam National Heart Institute and Hanoi Medical University Hospital between September 2022 and August 2023. The main objective is to evaluate the left ventricular systolic function following the intervention using 2D echocardiography. Results: A total of 40 patients (34 male and 6 females) with a mean age of 68.3 ± 10.2, were assessed for left ventricular systolic function using 2D echocardiography before and after the intervention. In paired assessment at 90-day follow-up, baseline LVEF improved significantly (before intervention: 32.8 ± 7.2% and after: 38,7 ± 7,3%, p \u003C 0.01). Left ventricular longitudinal strain improved significantly on all cross-sections such as: 4-chamber GLS (before: -10.4 ± 3.97%, after: -13.6 ± 4.3%, p \u003C 0.01), 2-chamber GLS (before: -10.6 ± 3.8%, after: -13.1 ± 4.2%, p \u003C 0.01), 3-chamber GLS (before: -9.8 ± 3.7%, after: -12.3 ± 4.6%, p \u003C 0.01), GLS Avg (before: -10.3 ± 3.6%, after: -13 ± 4.1%, p\u003C 0.01), basal GLS (before: -11.2 ± 3.8%, after: -14 ± 4.5%, p \u003C 0.01), middle GLS (before: -9.3 ± 4.4%, after: -11.8 ± 3.9%, p \u003C 0.01), apical GLS (before: -11.5 ± 5.1%, after: -14.3 ± 5.9%, p \u003C 0.01). In comparison with the incomplete-revascularization group, there was a significant improvement in left ventricular systolic function in the complete-revascularization group (OR= 22.17, p \u003C 0.01). Conclusions: In patients with chronic coronary syndrome and a reduced left ventricular ejection fraction, the systolic function of the left ventricle was enhanced following percutaneous coronary intervention, particularly in the group that underwent complete revascularization.",{"EN":1285},"Assessment of left ventricular systolic function in patients with chronic coronary syndrome and heart failure with reduced ejection fraction after percutaneous coronary intervention",{"VOID":1287},"10.58354\u002Fjvc.107e.2023.705","2026-06-17T15:29:55.807+00:00",[239],"https:\u002F\u002Ftapchitimmachhocvietnam.vn\u002Fj\u002Ftmh\u002Farticles\u002F702-assessment-of-left-ventricular-systolic-function-in-patients-with-chronic-coronary-syndrome-and-heart-failure-with-reduced-ejection-fraction-after-percutaneous-coronary-intervention?lang=vi-VN",[1292,1299,1306,1313,1320,1327,1334,1341],{"id":1293,"sortIndex":19,"researcher":18,"roles":1294,"affiliations":1295,"properties":1296},"13abaad8-1132-44ad-b7b1-5cd423f844b5",[],[],{"title":1297},{"EN":1298},"Dao Anh Tan",{"id":1300,"sortIndex":1230,"researcher":18,"roles":1301,"affiliations":1302,"properties":1303},"7c6a5732-04bb-494d-bb20-45f385225523",[],[],{"title":1304},{"EN":1305},"Nguyen Thi Hoa",{"id":1307,"sortIndex":203,"researcher":18,"roles":1308,"affiliations":1309,"properties":1310},"db4db82f-e049-4f9d-8af8-030ab99a3466",[],[],{"title":1311},{"EN":1312},"Nguyen Cong Thanh",{"id":1314,"sortIndex":29,"researcher":18,"roles":1315,"affiliations":1316,"properties":1317},"9697be65-4d3e-402c-a2ef-892ede588be3",[],[],{"title":1318},{"EN":1319},"Nguyen Do Quan",{"id":1321,"sortIndex":28,"researcher":18,"roles":1322,"affiliations":1323,"properties":1324},"a1ec0b06-6b98-4366-bfb6-b1319aedc1ba",[],[],{"title":1325},{"EN":1326},"Nguyen Lan Hieu",{"id":1328,"sortIndex":1205,"researcher":18,"roles":1329,"affiliations":1330,"properties":1331},"4ff0289a-78d9-4c18-9ef3-b7ca39da6c1b",[],[],{"title":1332},{"EN":1333},"Le Thi Men",{"id":1335,"sortIndex":189,"researcher":18,"roles":1336,"affiliations":1337,"properties":1338},"1ed88c92-3171-4097-9753-75f751e9dac0",[],[],{"title":1339},{"EN":1340},"Tran Ngoc Cam",{"id":1342,"sortIndex":30,"researcher":18,"roles":1343,"affiliations":1344,"properties":1345},"da9277bd-07af-4c0e-8af3-690d5a2164ae",[],[],{"title":1346},{"EN":1347},"Do Thuy Can",{"url":18,"publisher":1349,"properties":1362},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1350,"slug":10,"properties":1351,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1354,"manageAffiliations":1355,"indexDatabases":1356,"url":23,"thumbnailPath":18,"statistic":1357,"gsStatistic":18,"type":35,"analyzePriority":18},[],{"issn":1352,"title":1353},{"VOID":13},{"VOID":15},[],[],[],{"impactFactor":19,"impactFactorByYear":1358,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":26,"totalPublicationByYear":1359,"totalCitation":30,"totalCitationByYear":1360,"totalCitationPerPublication":32,"totalCitationPerPublicationByYear":1361,"hindexLast5Year":28,"hindex":28},{},{"2015":28,"2016":28,"2018":29,"2019":28,"2021":29,"2022":28,"2023":30},{"2015":28,"2018":28},{"2015":28,"2018":34},{"volume":1363,"pages":1365,"issue":1366},{"VOID":1364},"0",{"VOID":944},{"VOID":1367},"107","2023-11-30",2023,[],[1372,1374,1376,1378,1380,1382,1384,1386,1388,1390,1392,1394,1396,1398],{"id":18,"text":1373,"url":18,"identifiers":18},"Vedin O, Lam CSP, Koh AS, et al. Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study. Circ: Heart Failure. 2017;10(6):e003875. doi: 10.1161\u002FCIRCHEARTFAILURE.117.003875",{"id":18,"text":1375,"url":18,"identifiers":18},"Perera D, Clayton T, O’Kane PD, et al. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction. N Engl J Med. 2022;387(15):1351-1360. doi: 10.1056\u002FNEJMoa2206606",{"id":18,"text":1377,"url":18,"identifiers":18},"Velazquez EJ, Lee KL, Jones RH, et al. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med. 2016;374(16):1511-1520. doi: 10.1056\u002FNEJMoa1602001",{"id":18,"text":1379,"url":18,"identifiers":18},"DeVore AD, Yow E, Krucoff MW, et al. Percutaneous coronary intervention outcomes in patients with stable coronary disease and left ventricular systolic dysfunction. ESC Heart Failure. 2019;6(6):1233-1242. doi: 10.1002\u002Fehf2.12510",{"id":18,"text":1381,"url":18,"identifiers":18},"Wolff G, Dimitroulis D, Andreotti F, et al. Survival Benefits of Invasive Versus Conservative Strategies in Heart Failure in Patients With Reduced Ejection Fraction and Coronary Artery Disease: A Meta-Analysis. Circ: Heart Failure. 2017;10(1):e003255. doi: 10.1161\u002FCIRCHEARTFAILURE.116.003255",{"id":18,"text":1383,"url":18,"identifiers":18},"Pathak S, Lai FY, Miksza J, et al. Surgical or percutaneous coronary revascularization for heart failure: an in silico model using routinely collected health data to emulate a clinical trial. European Heart Journal. 2023;44(5):351-364. doi: 10.1093\u002Feurheartj\u002Fehac670",{"id":18,"text":1385,"url":18,"identifiers":18},"Velazquez EJ, Lee KL, Deja MA, et al. Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. N Engl J Med. 2011;364(17):1607-1616. doi: 10.1056\u002FNEJMoa1100356",{"id":18,"text":1387,"url":18,"identifiers":18},"Smiseth OA, Torp H, Opdahl A, et al. Myocardial strain imaging: how useful is it in clinical decision making? Eur Heart J. 2016;37(15):1196-1207. doi: 10.1093\u002Feurheartj\u002Fehv529",{"id":18,"text":1389,"url":18,"identifiers":18},"Blessberger H, Binder T. Two dimensional speckle tracking echocardiography: clinical applications. Heart. 2010;96(24):2032-2040. doi: 10.1136\u002Fhrt.2010.199885",{"id":18,"text":1391,"url":18,"identifiers":18},"Lobo AS, Cantu SM, Sharkey SW, et al. Revascularization in Patients With Spontaneous Coronary Artery Dissection and ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology. 2019;74(10):1290-1300. doi: 10.1016\u002Fj.jacc.2019.06.065",{"id":18,"text":1393,"url":18,"identifiers":18},"Bangalore S, Guo Y, Samadashvili Z, et al. Outcomes With Complete Versus Incomplete Revascularization in Patients With Multivessel Coronary Disease Undergoing Percutaneous Coronary Intervention With Everolimus Eluting Stents. The American Journal of Cardiology. 2020;125(3):362-369. doi: 10.1016\u002Fj.amjcard.2019.10.022",{"id":18,"text":1395,"url":18,"identifiers":18},"Kramer DG, Trikalinos TA, Kent DM, et al. Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction. Journal of the American College of Cardiology. 2010;56(5):392-406. doi: 10.1016\u002Fj.jacc.2010.05.011",{"id":18,"text":1397,"url":18,"identifiers":18},"Adachi Y, Sakakura K, Wada H, et al. Determinants of Left Ventricular Systolic Function Improvement Following Coronary Artery Revascularization in Heart Failure Patients With Reduced Ejection Fraction (HFrEF). Int Heart J. 2016;57(5):565-572. doi: 10.1536\u002Fihj.16-087",{"id":18,"text":1399,"url":18,"identifiers":18},"Russo JJ, Prasad M, Doshi D, et al. Improvement in left ventricular function following higher‐risk percutaneous coronary intervention in patients with ischemic cardiomyopathy. Cathet Cardio Intervent. 2020;96(4):764-770. doi: 10.1002\u002Fccd.28557",{"id":1401,"createTime":1402,"updateTime":1403,"relativeEntities":1404,"slug":1405,"properties":1406,"entityType":54,"verifyStatus":55,"verifyTime":1415,"verifyNote":56,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1416,"fullTextUrl":1417,"authors":1418,"publicationType":110,"publisherRelationship":1466,"citationCount":19,"citationInfo":1485,"publishDate":1488,"publishYear":1486,"citationAnalyzeStatus":1489,"lastCitationAnalyze":1490,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":152},"08216f12-3795-4f1a-99f3-609a5bae95e2","2024-02-20T18:46:09.177+00:00","2026-06-11T14:41:09.383+00:00",[],"K%E1%BA%BFt-qu%E1%BA%A3-t%E1%BB%A9c-th%E1%BB%9Di-v%C3%A0-trung-h%E1%BA%A1n-c%E1%BB%A7a-ph%C6%B0%C6%A1ng-ph%C3%A1p-b%C3%ADt-th%C3%B4ng-li%C3%AAn-th%E1%BA%A5t-kh%C3%B4ng-c%C3%B3-g%E1%BB%9D-van-%C4%91%E1%BB%99ng-m%E1%BA%A1ch-ch%E1%BB%A7-b%E1%BA%B1ng-d%E1%BB%A5ng-c%E1%BB%A5-ADOII-qua-%C4%91%C6%B0%E1%BB%9Dng-%E1%BB%91ng-th%C3%B4ng",{"references":1407,"gsPaper":1409,"abstract":1411,"title":1413},{"VOID":1408},"1. T. Carol. Diseases of the Human Body. Philadelphia. Fifth. PA: F.A Davis Company; 2011.\n2. Van der Linde D, Konings EEM, Slager MA, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58(21):2241-2247. doi:10.1016\u002Fj.jacc.2011.08.025.\n3. Phạm Nguyễn Vinh. Bệnh Học Tim Mạch Tập II. Nhà xuất bản Y học.; 2008.\n4. Zhou T, Luo Y, Zhou X. Transcatheter Closure vs Surgical Closure of Ventricular Septal Defect in China: A Meta-Analysis. Cross-Cult Commun. 2015;11(9):57-65. doi:10.3968\u002F%x\n5. Phạm Tuấn Việt. Đánh giá kết quả ngắn hạn và trung hạn can thiệp bít thông liên thất bằng dụng cụ qua đường ống thông ở người trưởng thành. Published online 2015.\n6. Nguyễn Lân Hiếu. Lâm Sàng Tim Bẩm Sinh. Nhà xuất bản Đại học Quốc Gia Hà Nội; 2021.\n7. Kanaan M, Ewert P, Berger F, Assa S, Schubert S. Follow-Up of Patients with Interventional Closure of Ventricular Septal Defects with Amplatzer Duct Occluder II. Pediatr Cardiol. 2015;36(2):379-385. doi:10.1007\u002F s00246-014-1017-0.\n8. Kuswiyanto RB, Rahayuningsih SE, Apandi PR, Hilmanto D, Bashari MH. Transcatheter closure of doubly committed subarterial ventricular septal defect: Early to one-year outcome. Int J Cardiol Congenit Heart Dis. 2021;2:100081. doi:10.1016\u002Fj.ijcchd.2021.100081.\n9. Masura J, Gao W, Gavora P, et al. Percutaneous Closure of Perimembranous Ventricular Septal Defects with the Eccentric Amplatzer Device: Multicenter Follow-up Study. Pediatr Cardiol. 2005;26(3):216-219. doi:10.1007\u002F s00246-005-1003-7.\n10. Koneti NR, Penumatsa RR, Kanchi V, Arramraj SK, S. J, Bhupathiraju S. Retrograde transcatheter closure of ventricular septal defects in children using the Amplatzer Duct Occluder II. Catheter Cardiovasc Interv. 2011;77(2):252-259. doi:10.1002\u002Fccd.22675.",{"VOID":1410},"18034249183042264254",{"VI":1412},"Mục tiêu: Mô tả kết quả trung hạn của phương pháp bít thông liên thất không có gờ van động mạch chủ bằng dụng cụ ADOII qua đường ống thông.\r\nĐối tượng và phương pháp nghiên cứu: nghiên cứu quan sát trên 31 bệnh nhân được chẩn đoán thông liên thất không có gờ van động mạch chủ (TLT phần quanh màng lan đến sát van động mạch chủ và thông liên thất dưới đại động mạch) đã được can thiệp bằng dụng cụ ADO II qua đường ống thông tại Viện Tim mạch Việt Nam từ tháng 4\u002F2015 đến tháng 4\u002F2021\r\nKết quả: có tổng số 31 bệnh nhân thông liên thất không có gờ van động mạch chủ (24 BN TLT phần quanh màng không có gờ van ĐMC; 27 BN TLT dưới hai đại động mạch), gồm 20 BN nam và 11 BN nữ. Tuổi trung bình 17,84 (2-46 tuổi), cân nặng trung bình 34,81 kg (10 – 60 kg) đường kính trung bình thông liên thất phía thất phải: 3,65\r\n± 1,15 mm; đường kính trung bình thông liên thất phía thất trái: 5,00 ± 1,77 mm được can thiệp bít lỗ thông bằng dụng cụ ADOII. Tỷ lệ thành công của thủ thuật là 96,77%. Sau can thiệp, áp lực động mạch phổi giảm có ý nghĩa thống kê so với trước can thiệp với p = 0,03. Thời gian theo dõi sau can thiệp trong nghiên cứu là 45,39 ± 31,81 tháng (6- 72 tháng). Tại thời điểm 6 tháng sau can thiệp, gần\r\n \r\ncan thiệp, sau 60 tháng, tỷ lệ bệnh nhân còn triệu chứng khó thở tức ngực chỉ chiếm gần 5% so với trước can thiệp. Tại thời điểm 6 tháng sau can thiệp, có 82,75% bệnh nhân hết shunt tồn lưu, tại thời điểm 60 tháng sau can thiệp, chỉ còn 11,11% bệnh nhân còn shunt tồn lưu nhỏ và rất nhỏ, không ảnh hưởng tới huyết động. Tỷ lệ hở van động mạch chủ, van nhĩ thất trước và sau can thiệp khác biệt không có ý nghĩa thống kê. Không có trường hợp nào ghi nhận bloc nhĩ thất, không có trường hợp nào ghi nhận các biến chứng trầm trọng: tràn dịch màng tim, viêm nội tâm mạc nhiễm khuẩn, hở van tim tiến triển. Không có trường hợp nào di lệch dụng cụ phải xử trí, không có trường hợp nào tử vong trong quá trình theo dõi.\r\nKết luận: Tỷ lệ thành công của phương pháp bít thông liên thất không có gờ van động mạch chủ bằng dụng cụ ADOII qua đường ống thông trong nghiên cứu đạt 96,77%. Tỷ lệ bít kín hoàn toàn đạt 82,75% sau can thiệp 6 tháng và 99,89% sau can thiệp 60 tháng. Không có biến chứng trầm trọng: hở van động mạch chủ, hở van nhĩ thất tiến triển, rối loạn nhịp tim trong thời gian theo dõi 45,39 ± 31,81 tháng (6-72 tháng).\r\nTừ khóa: thông liên thất, gờ van động mạch chủ, can thiệp qua đường ống thông.",{"VI":1414},"Kết quả tức thời và trung hạn của phương pháp bít thông liên thất không có gờ van động mạch chủ bằng dụng cụ ADOII qua đường ống thông","2025-01-12T05:47:32.249+00:00","https:\u002F\u002Fjvc.vnha.org.vn\u002Ftmh\u002Farticle\u002Fview\u002F338","https:\u002F\u002Fjvc.vnha.org.vn\u002Ftmh\u002Farticle\u002Fdownload\u002F338\u002F332",[1419,1434,1450],{"id":1420,"sortIndex":19,"researcher":18,"roles":1421,"affiliations":1422,"properties":1431},"0931339a-994d-44cd-9844-8032ec5a9920",[1126],[1423],{"id":18,"sortIndex":19,"affiliation":1424,"properties":18},{"id":1425,"createTime":1426,"updateTime":1426,"relativeEntities":1427,"slug":18,"properties":1428,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"f4021d3f-ef0f-432c-b4d7-5b6b5a229233","2024-02-20T18:46:09.209+00:00",[],{"title":1429},{"VI":1430},"Bộ môn Tim mạch - Trường Đại học Y Hà Nội",{"title":1432},{"VI":1433},"Hoàng Kim Quân",{"id":1435,"sortIndex":28,"researcher":18,"roles":1436,"affiliations":1437,"properties":1447},"fa6af91a-a113-40d6-a2b4-862f56e6b042",[1126],[1438],{"id":1439,"sortIndex":19,"affiliation":1440,"properties":1445},"2ae7f575-552b-4d5b-acf1-f424089380d7",{"id":372,"createTime":373,"updateTime":374,"relativeEntities":1441,"slug":376,"properties":1442,"entityType":76,"verifyStatus":55,"verifyTime":382,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":26},[],{"country":1443,"title":1444},{"VOID":228},{"EN":380,"VI":381},{"title":1446},{"VI":93},{"title":1448},{"VI":1449},"Nguyễn Văn Hiếu",{"id":1451,"sortIndex":30,"researcher":18,"roles":1452,"affiliations":1453,"properties":1464},"4a655cfe-f3df-4368-9133-67d24e570ddd",[1126],[1454],{"id":18,"sortIndex":19,"affiliation":1455,"properties":18},{"id":1456,"createTime":1457,"updateTime":1458,"relativeEntities":1459,"slug":1460,"properties":1461,"entityType":76,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"e79a8923-ee23-4b7e-b2ad-85e9030ed8f7","2024-02-20T18:46:09.232+00:00","2024-09-18T07:12:32.373+00:00",[],"B%E1%BB%99-m%C3%B4n-Tim-m%E1%BA%A1ch-Tr%C6%B0%E1%BB%9Dng-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Y-H%C3%A0-N%E1%BB%99i-B%E1%BB%87nh-vi%E1%BB%87n-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Y-H%C3%A0-N%E1%BB%99i-",{"title":1462},{"VI":1463},"Bộ môn Tim mạch - Trường Đại học Y Hà Nội, Bệnh viện Đại học Y Hà Nội ",{"title":1465},{"VI":1166},{"url":1416,"publisher":1467,"properties":1480},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1468,"slug":10,"properties":1469,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1472,"manageAffiliations":1473,"indexDatabases":1474,"url":23,"thumbnailPath":18,"statistic":1475,"gsStatistic":18,"type":35,"analyzePriority":18},[],{"issn":1470,"title":1471},{"VOID":13},{"VOID":15},[],[],[],{"impactFactor":19,"impactFactorByYear":1476,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":26,"totalPublicationByYear":1477,"totalCitation":30,"totalCitationByYear":1478,"totalCitationPerPublication":32,"totalCitationPerPublicationByYear":1479,"hindexLast5Year":28,"hindex":28},{},{"2015":28,"2016":28,"2018":29,"2019":28,"2021":29,"2022":28,"2023":30},{"2015":28,"2018":28},{"2015":28,"2018":34},{"pages":1481,"issue":1483},{"VOID":1482},"62-68",{"VOID":1484},"101",{"total":19,"publishYear":1486,"statisticByYear":1487},2022,{},"2022-09-01","ERROR_IN_ANALYZE_CITATION","2026-06-11T14:41:09.382+00:00"]